Document:

Exhibit 10.1

 

AMENDED AND RESTATED EARLY ACCESS AGREEMENT

 

This exclusive Early Access Agreement
(“Agreement”) is made and entered into the 20th day of May, 2016, (“Effective Date”)
by and between

 

Hemispherx
Biopharma, Inc, a company formed and registered under the laws of Delaware and located at One Penn Center, 1617 JFK Boulevard,
Suite 500, Philadelphia, PA 19103, U.S.A. (hereinafter
referred to as “HEMISPHERX”),

 

and

 

Impatients N.V., a company formed
and registered under the laws of the Netherlands, and located at Pilotenstraat 45, 1059 CH, Amsterdam, The Netherlands (hereinafter
referred to as “IMPATIENTS”),  

 

hereinafter each of HEMISPHERX and IMPATIENTS,
referred individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS,
HEMISPHERX has developed, and is developing the Product (as defined below), and owns or controls certain patent rights, and technical
and scientific information relating to, and the global exclusive rights to distribute, market and sell Product,

 

WHEREAS,
IMPATIENTS specialises under the brand myTomorrows in services related to the supply
and distribution of products to patients in Early Access Programs (also referred to as EAP and as defined below) through a patient
and physician platform (hereinafter referred to as the “myTomorrows platform”),

 

WHEREAS,
HEMISPHERX is willing to grant IMPATIENTS the exclusive right to develop and execute Early Access Programs in the Territory (as
defined below) and to supply quantities of Product to IMPATIENTS for these Early Access Programs in the Territory,

 

WHEREAS,
IMPATIENTS agrees to accept such right and to use the Product for Early Access Programs from
HEMISPHERX pursuant to the terms of this Agreement, and

 

WHEREAS,
the Parties wish to set forth the terms and conditions under which HEMISPHERX grants the exclusive right and supplies the Product
and IMPATIENTS implements the Early Access Program.

 

NOW THEREFORE, in consideration of the
foregoing premises and the mutual covenants set forth below, the Parties hereto, intending to be legally bound, agree as follows:

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	1

     

    

 

1. Definitions

 

The following
terms when used in this Agreement, shall have the meanings set forth in this clause:

 

		1.1	“Accounting Standards”
                                         with respect to a Party means that such Party shall maintain records and books of accounts
                                         in accordance with International Financial Reporting Standards as issued by the International
                                         Accounting Standards Board.

 

		1.2	“Affiliate” means,
                                         as to any person or entity, any other person or entity, which controls, is controlled
                                         by, or is under common control with such person or entity. A person or entity shall be
                                         regarded as in control of another entity only if it owns or controls, directly or indirectly,
                                         at least fifty percent (50%) of the equity securities or other ownership interests in
                                         the subject entity entitled to vote in the election of directors or with the power to
                                         direct or elect management of such subject entity.

 

		1.3	“HEMISPHERX Patents”
                                         means all of the Patents that are (a) under Control by HEMISPHERX or any of its Affiliates
                                         as of the Effective Date or at any time during the Term, and (b) reasonably necessary
                                         or useful (or, with respect to Patent applications, would be reasonably necessary or
                                         useful if such Patent applications were to issue as Patents) for the development, manufacture,
                                         or use or sale of the Product.

 

		1.4	“Applicable Law”
                                         means federal, state, local, national and supra-national laws, statutes, rules, and regulations,
                                         including any rules, regulations, guidelines, or other requirements of the Regulatory
                                         Authorities, major national securities exchanges or major securities listing organizations,
                                         that may be in effect from time to time during the Term and applicable to a particular
                                         activity and/or country or other jurisdiction hereunder.

 

		1.5	“Confidential Information”
                                         means any Information provided orally, visually, in writing or other form by or on behalf
                                         of one Party to the other Party in connection with this Agreement, whether prior to,
                                         on, or after the Effective Date, including information relating to the terms of this
                                         Agreement, the Product (including the Regulatory Documentation and Regulatory Data),
                                         any use of the Product, any know-how with respect thereto developed by or on behalf of
                                         the disclosing Party or its Affiliates, or the scientific, regulatory or business affairs
                                         or other activities of either Party. Notwithstanding the foregoing, (a) jointly
                                         owned Know-How shall be deemed to be the Confidential Information of both Parties, and
                                         both Parties shall be deemed to be the receiving Party and the disclosing Party with
                                         respect thereto; and (b) after IMPATIENTS proceeds with the EAP, all Regulatory
                                         Documentation developed by IMPATIENTS shall be deemed to be the Confidential Information
                                         of HEMISPHERX, and HEMISPHERX shall be deemed to be the disclosing Party and IMPATIENTS
                                         shall be deemed to be the receiving Party with respect thereto.

 

		1.6	“Control” means,
                                         with respect to any item of Information, Regulatory Documentation, material, Patent,
                                         or other property right existing on or after the Effective Date and during the Term,
                                         the possession of the right, whether directly or indirectly, and whether by ownership,
                                         license, covenant not to sue, or otherwise (other than by operation of the license and
                                         other grants herein), to grant a license, sublicense or other right (including the right
                                         to reference Regulatory Documentation) to or under such Information, Regulatory Documentation,
                                         material, Patent, or other property right as provided for herein without violating the
                                         terms of any agreement or other arrangement with any third party; provided, however,
                                         neither Party shall be deemed to Control any item of Information, Regulatory Documentation,
                                         material, Patent, or other property right of a third party if access requires or triggers
                                         a payment obligation.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	2

     

    

 

		1.7	“Early Access Program”
                                         or “EAP” means the activities directed to (a) the education of physicians
                                         and patients regarding the possibility of early access to innovative medical treatments
                                         not yet the subject of a Marketing Authorization through named-patient use, compassionate
                                         use, expanded access and hospital exemption (b) patient and physician outreach related
                                         to the platform, (c) the securing of Early Access Approvals, for the use of such treatments,
                                         (d) the distribution and sale of such treatments pursuant to such Early Access Approvals,
                                         (e) pharmacovigilance activities in accordance with the Pharmacovigilance agreement,
                                         attached as Exhibit 6 and/or (f) to the extent permitted by Applicable Law, the collection
                                         of data, including but not limited to patient-reported outcomes, doctor-reported experiences
                                         and registry data as set out in more detail in Exhibit 9.

 

		1.8	“EAP Plan” means
                                         the plan to be agreed by the JSC for the initiation and performance of an Early Access
                                         Program for Product in the Field. The EAP Plan will be attached hereto as Exhibit 1.

 

		1.9	“Early Access Approvals”
                                         means the permissions, exemptions, approvals, authorizations and/or waivers required
                                         by Regulatory Authorities for medical treatments, not subject of a Marketing Authorization
                                         in the relevant country, to be sold to a pharmacy or wholesaler, to be dispensed to a
                                         physician, to be administered to and/or used by a patient.

 

		1.10	“Field” means treatment
                                         of chronic fatigue syndrome.

 

		1.11	“First Commercial Sale”
                                         means, with respect to a Product and a country, the first sale for monetary value for
                                         ultimate use by the patient of such Product in such country after Marketing Authorization
                                         for such Product has been obtained in such country. Sales prior to receipt of Marketing
                                         Authorization for such Product, such as so-called “treatment IND sales,”
                                         “named patient sales,” or other “compassionate use sales,” shall
                                         not be construed as a First Commercial Sale.

 

		1.12	“Good Manufacturing Practice”
                                         or “GMP” means the current good manufacturing practices applicable
                                         from time to time to the manufacturing of a Product or any intermediate thereof pursuant
                                         to Applicable Law.

 

		1.13	“Information” means
                                         knowledge of a technical, scientific, business, and other nature, including know-how,
                                         technology, means, methods, processes, practices, formulae, instructions, skills, techniques,
                                         procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures,
                                         computer programs, apparatuses, specifications, data, results and other material, Regulatory
                                         Data, and other biological, chemical, pharmacological, toxicological, pharmaceutical,
                                         physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control
                                         data and information, including study designs and protocols; assays, and biological methodology;
                                         in each case (whether or not confidential, proprietary, patented or patentable, of commercial
                                         advantage or not) in written, electronic or any other form now known or hereafter developed.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	3

     

    

 

		1.14	“Joint Steering Committee
                                         or JSC” means the joint steering committee to be established by the Parties
                                         as referred to in Clause 2.

 

		1.15	“Know How” means
                                         information and materials, whether or not confidential, including, but not limited to,
                                         pharmaceutical, chemical, products, economic and commercial information, including and
                                         not limited to all market information, strategies and tactics relevant to the Product
                                         in the Territory and any lists of physicians and/or clinicians active in the Field in
                                         the Territory, technical and non-technical manufacturing process and equipment data and
                                         information, product and process validation data, the results of tests on products, reports
                                         and results of product assays, pre-clinical and clinical studies, and drawings, plans,
                                         diagrams, specifications and/or other documents containing said information relating
                                         to the Product.

 

		1.16	“Manufacturer“
                                         means the legal entity that physically manufactures and/or fills and/or finishes and/or
                                         labels and/or stockpiles cGMP grade Product.

 

		1.17	“Marketing Authorization”
                                         means, with respect to a country, region or other jurisdiction in the Territory and in
                                         the Field, any and all approvals (including Drug Approval Applications), licenses, registrations,
                                         or authorizations of any Regulatory Authority necessary to commercially distribute, sell,
                                         or market Product in the Field in such country or other jurisdiction, including, where
                                         applicable, (a) pre- and post-approval regulatory approvals (including any prerequisite
                                         manufacturing approval or authorization related thereto), and (b) approval of Product
                                         labeling in the Field.

 

		1.18	“Material Event”
                                         means, in the context of the EAP, any event which would, in HEMISPHERX’s reasonable
                                         opinion, (a) adversely affect HEMISPHERX’s ability to market and distribute the
                                         Product outside of the EAP, including but not limited to its ability to obtain Marketing
                                         Authorisation in any country or region, (b) adversely effect HEMISPHERX’s ability
                                         to use its intellectual property relating to its brand or the Product, or (c) bring HEMISPHERX’s
                                         business into disrepute. For the avoidance of doubt, a Material Event shall not include
                                         any event relating to the performance of pharmacovigilance activities in relation to
                                         which the Parties have entered into the Pharmacovigilance Agreement.

 

		1.19	“Net EAP Sales”
                                         means the gross amount invoiced by IMPATIENTS or its affiliates to non-affiliated third
                                         parties for the sale of Product, less the following reasonable and customary deductions
                                         consistent with IMPATIENTS’ cash or accrual accounting method to the extent applicable
                                         to such invoiced amounts (to the extent each is actually incurred and included in the
                                         invoiced gross sales price) in accordance with Accounting Standards:

 

		(a)	all mutually agreed trade discounts
                                         or rebates;

 

		(b)	amounts for claims, allowances or
                                         credits for rejections or returns;

 

		(c)	packaging, handling fees and costs
                                         of freight, insurance, sales taxes, duties and other governmental charges (including
                                         value added tax), but excluding what is commonly known as income taxes.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

    	 	 	4

     

    

 

The specific
deductions, as set out in Exhibit 8, taken under, and the general provision of, (a) through (c) above may be adjusted periodically
after agreement between both Parties as necessary to reflect amounts actually incurred.

 

		1.20	“Net Sales” means
                                         the gross amount invoiced by HEMISPHERX or its affiliates to non-affiliated third parties
                                         for the sale of Product, less the following reasonable and customary deductions consistent
                                         with HEMISPHERX’s cash or accrual accounting method to the extent applicable to
                                         such invoiced amounts (to the extent each is actually incurred and included in the invoiced
                                         gross sales price) in accordance with Accounting Standards:

 

		(a)	all mutually agreed trade discounts,
                                         or rebates;

 

		(b)	amounts for claims, allowances or
                                         credits for rejections or returns;;

 

		(c)	packaging, handling fees and costs
                                         of freight, insurance, sales taxes, duties and other governmental charges (including
                                         value added tax), but excluding what is commonly known as income taxes.

 

The specific
deductions taken under, and the general provision of, (a) through (c) above may be adjusted periodically after agreement between
both Parties as necessary to reflect amounts actually incurred.

 

For the avoidance
of doubt, Net Sales shall not include sales for resale to Affiliates of HEMISPHERX.

 

For purpose
of this definition 1.20, a sale shall also include a transfer or other disposition for consideration other than cash, in which
case such consideration shall be valued at the fair market value thereof. Transfers or dispositions for charitable purposes or
for pre-clinical, clinical, regulatory or governmental purposes prior to receiving Marketing Authorization are not considered
a "sale".

 

		1.21	“Patents”
                                         means (a) all national, regional and international patent applications, including provisional
                                         patent applications, and all applications claiming priority therefrom, including divisionals,
                                         continuations, continuations-in-part, provisionals, converted provisionals and continued
                                         prosecution applications; (b) any and all national patents issued or granted from
                                         the foregoing patent applications, including utility patents, utility models, petty patents
                                         and design patents and certificates of invention; (c) any and all extensions or
                                         restorations by existing or future extension or restoration mechanisms, including revalidations,
                                         reissues, re-examinations and extensions (including any supplementary protection certificates
                                         and the like) of the foregoing patents or patent applications ((a) and (b)); and (d)
                                         any similar rights, including so-called pipeline protection or any importation, revalidation,
                                         confirmation or introduction patent or registration patent or patent of additions to
                                         any of such foregoing patent applications and patents. 

 

		1.22	“Patient on Treatment”
                                         means patients that have met all the criteria to receive the Product under an EAP as
                                         set out in the EAP Plan and who have had the Product prescribed for them.

 

		1.23	Pharmacovigilance Agreement”
                                         or “PhVA” means the pharmacovigilance agreement attached as Exhibit 6.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	5

     

    

 

		1.24	“Price” means
                                         the price of Product invoiced by IMPATIENTS to third parties other than Affiliates of
                                         IMPATIENTS in accordance with Exhibit 4 excluding any VAT or other taxes or levies that
                                         are applicable.

 

		1.25	“Product”
                                         means all available stock-keeping units (SKU)’s of the product referred to as of
                                         the Effective Date, as Ampligen®, a double-stranded RNA product, supplied
                                         ready packed and labeled, such labeling to include the Ampligen Trademark and the fact
                                         that the Product is manufactured and supplied by HEMISPHERX on both primary and secondary
                                         containers, quality tested and QP released in accordance with applicable pharmaceutical
                                         law and regulations.

 

		1.26	“Quality Agreement
                                         or QA ” means the quality agreement attached as Exhibit 5 to this Agreement.

 

		1.27	“Regulatory Authority”
                                         means any applicable supra-national, federal, national, regional, state, provincial,
                                         or local governmental or regulatory authority, agency, department, bureau, commission,
                                         council, or other entities (e.g., the FDA, EMA and PMDA) regulating or otherwise exercising
                                         authority with respect to activities contemplated in this Agreement.

 

		1.28	“Regulatory Data”
                                         shall have the meaning given to it in Clause 4.2 of this Agreement.

 

		1.29	“Regulatory Documentation”
                                         means all (a) applications (including all INDs and Drug Approval Applications and
                                         other regulatory filings), registrations, licenses, authorizations, and approvals (including
                                         Regulatory Approvals); (b) correspondence and reports submitted to or received from
                                         Regulatory Authorities (including minutes and official contact reports relating to any
                                         communications with any Regulatory Authority) and all supporting documents with respect
                                         thereto, including all regulatory drug lists, advertising and promotion documents, adverse
                                         event files, and complaint files; and (c) pre-clinical and clinical data, and data
                                         contained or relied upon in any of the foregoing, in each case (a), (b), and (c) relating
                                         to Product.

 

		1.30	“Specifications”
                                         means all data necessary to manufacture the Product and contained in the most recent
                                         version of the product specification file, IMPD or IND.

 

		1.31	“Territory”
                                         means all the countries of the European Union and Turkey.

 

		1.32	“Trademark”
                                         means any word, name, symbol, color, designation or device or any combination thereof
                                         that functions as a source identifier, including any trademark, trade dress, brand mark,
                                         service mark, trade name, brand name, logo, business symbol or domain names whether or
                                         not registered.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	6

     

    

  

			2     –
EAP activities & management

  

		2.1	EAP Activities.

 

IMPATIENTS shall perform EAP
activities, including selling and distributing the Product in the Territory. IMPATIENTS shall use reasonable commercial efforts
to assure that all requested and relevant information is presented to regulatory authorities, decision makers, patients and/or
responsible medical specialists, including informing patients and health care practitioners in general about their opportunities
to apply for Early Access Approvals in the Territory.

 

		2.2	Collaborative Committees.

 

As soon as practical after the
Effective Date, but no later than thirty (30) days thereafter, the Parties shall establish a joint steering committee (the “Joint
Steering Committee” or “JSC”), which shall (a) oversee the EAP plan for the Product in the Territory, (b) resolve
Disputes that may arise in any subcommittees formed by the JSC, (c) coordinate the Parties’ activities under this Agreement,
including oversight of any subcommittees formed by the JSC, and (d) perform such other functions as are set forth herein
or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement. The details of
the composition, operating procedures and responsibilities of the Collaborative Committees are described in Exhibit 2.

 

		2.3	Packaging.

 

Subject to the provision by HEMISPHERX
of appropriately labeled and packaged Product and associated materials, IMPATIENTS shall ensure that such amounts of the Product
and its associated materials as are supplied and distributed under the EAP Program shall prominently display the Product Trademark,
together with the information that the Product is manufactured and supplied by HEMISPHERX.

 

			3    –
                                         Grants of rights, disclosure of know how

 

		3.1	Appointment.

 

		3.1.1	HEMISPHERX
                                         hereby appoints IMPATIENTS as its exclusive service provider to perform EAP activities
                                         for Product in the Field in the Territory. 

 

		3.1.2	HEMISPHERX hereby grants IMPATIENTS
                                         an exclusive, non-transferable, royalty-free right to reproduce and use the Product’s
                                         Trademarks solely in connection with performing the EAP activities for Product in the
                                         Field in the Territory, subject to the terms and conditions set forth herein, including
                                         in Exhibit 3.

 

		3.2	IMPATIENTS
                                         Know How Contribution. 

 

IMPATIENTS
undertakes to contribute its Know How to perform the EAP, including but not limited its EAP technical and business knowledge regarding
patient and physician outreach, regulatory and legal support, pharmacovigilance, reimbursement, data collection, logistics and
marketing.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

    	 	 	7

     

    

  

		3.3	HEMISPHERX
                                         Know How Disclosure. 

 

Immediately
after the Effective Date, HEMISPHERX shall collaborate with IMPATIENTS make available to IMPATIENTS, in whatever form IMPATIENTS
may reasonably request, Regulatory Documentation, HEMISPHERX Know How, and any other Information relating directly or indirectly
to the Product and reasonably required to implement and manage the EAP in the Territory (including, but not limited to, information
related to Manufacturing), to the extent not done so already, and thereafter immediately upon the availability of such Regulatory
Documentation, HEMISPHERX Know How, or other Information. For the avoidance of doubt, where necessary, HEMISPHERX will and shall
cause its Affiliates and collaborators, without additional compensation, to make available to IMPATIENTS relevant information
agreed upon with IMPATIENTS under this Clause 3.3.

 

		3.4	HEMISPHERX
                                         Know How Assistance. 

 

HEMISPHERX,
at its sole cost and expense, shall provide IMPATIENTS with reasonable assistance required in order to transfer to IMPATIENTS
the Regulatory Documentation, HEMISPHERX Know How and other Information required to be produced hereunder, in each case in a timely
manner. HEMISPHERX shall reasonably assist IMPATIENTS with respect to the implementation of the EAP for the Product. 

 

			4    - Regulatory matters

 

		4.1	Regulatory
                                         Activities.

 

		4.1.1	IMPATIENTS
                                         shall have the sole and exclusive right to make contact with patients and physicians
                                         relating to the EAP of Product, and to file applications for Early Access Approvals therefor
                                         (including the setting of the overall regulatory strategy therefor), and to communicate
                                         with the Regulatory Authorities to secure Early Access Approvals for Product in the Territory.
                                         HEMISPHERX shall support IMPATIENTS as may be reasonably necessary in obtaining Early
                                         Access Approvals for the Product, and in the activities in support thereof, including
                                         providing necessary documents or other materials required by Applicable Law to obtain
                                         Early Access Approvals, in each case in accordance with the terms and conditions of this
                                         Agreement.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

 

    	 	 	8

     

    

  

		4.1.2	HEMISPHERX
                                         shall collaborate with IMPATIENTS to provide IMPATIENTS with (a) access to or copies
                                         of all material written or electronic correspondence (other than regulatory filings)
                                         relating to the development of Product in the Field received by HEMISPHERX or its Affiliates,
                                         collaborators or licensees from, or filed by HEMISPHERX or its Affiliates, collaborators
                                         or licensees with, the Regulatory Authorities, and (b) copies of all meeting minutes
                                         and summaries of all meetings, conferences, and discussions held by HEMISPHERX or its
                                         Affiliates, collaborators or licensees with the Regulatory Authorities relating to the
                                         development or commercialization of Product in the Field, including copies of all contact
                                         reports produced by HEMISPHERX or its Affiliates or licensees, in each case ((a) and
                                         (b)) within fifteen (15) Business Days of its receipt, forwarding or production of the
                                         foregoing, as applicable. If such written or electronic correspondence received from
                                         any such Regulatory Authority relates to the withdrawal, suspension, or revocation of
                                         a Regulatory Approval or Early Access Approval for Product in the Field, the prohibition
                                         or suspension of the supply of a Product in the Field, or the initiation of any investigation,
                                         review, or inquiry by such Regulatory Authority concerning the safety and quality of
                                         a Product in the Field, the notified Party shall notify the other Party and provide the
                                         other Party with copies of such written or electronic correspondence as soon as practicable.

 

		4.1.3	HEMISPHERX
                                         shall, in accordance with the Quality Agreement, make every reasonable effort to notify
                                         IMPATIENTS promptly following its determination that any event, incident, or circumstance
                                         has occurred that may result in the need for a recall, market suspension, or market withdrawal
                                         of a Product in the Territory in the Field, and shall include in such notice the reasoning
                                         behind such determination, and any supporting facts. HEMISPHERX (or its licensee) shall
                                         have the right to make the final determination whether to voluntarily implement any such
                                         recall, market suspension, or market withdrawal in the Territory. If a Regulatory Authority
                                         in the Territory mandates a recall, market suspension, or market withdrawal, then HEMISPHERX
                                         (or its licensee) shall initiate such a recall, market suspension, or market withdrawal
                                         in compliance with Applicable Law. For all recalls, market suspensions or market withdrawals
                                         undertaken pursuant to this Section 4.1.3, HEMISPHERX or its licensee, whichever responsible
                                         for the recall, market suspension, or market withdrawal, shall be solely responsible
                                         for the execution thereof, and IMPATIENTS shall reasonably cooperate in all such recall
                                         efforts.

 

		4.2	Regulatory
                                         Data.

 

Within the Field, each
Party shall promptly provide to the other Party copies of, or access to all non-clinical and clinical data, and other information,
results, and analyses with respect to any development activities that are carried out by on or behalf of or otherwise controlled
by such Party or any of its Affiliates, collaborators or licensees (collectively, “Regulatory Data”), when such Regulatory
Data becomes available. For the avoidance of doubt, the requirements under this Clause 4.2 shall include that HEMISPHERX shall
provide IMPATIENTS with copies of up-to-date versions of (a) the EU GMP certificate of the manufacturing site, (b) if applicable,
the Product’s GMP certificate, (c) the Manufacturer’s manufacturing license for the Product, (d) Product stability
data and certificate of analysis, together with all other Know How that IMPATIENTS is required to include, or may need to include,
in its Early Access Approval applications.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	9

     

    

 

		4.3	Pharmacovigilance.

 

Parties shall enter into a separate
agreement related to the responsibility and performance of pharmacovigilance activities related to the Product. This Pharmacovigilance
Agreement is attached as Exhibit 6.

 

		4.4	Compliance.

 

Each Party shall perform or
cause to be performed, any and all of its development activities, in good scientific manner and in compliance with all Applicable
Law.

 

		4.5	Records.

 

		4.5.1	Each
                                         of HEMISPHERX and IMPATIENTS shall, and shall ensure that its third party providers shall,
                                         maintain records in sufficient detail and in good scientific manner appropriate for regulatory
                                         purposes, and in compliance with Applicable Law, which shall be complete and accurate
                                         and shall properly reflect all work done and results achieved in the performance of its
                                         activities. HEMISPHERX or IMPATIENTS shall and retain all such records, as the case may
                                         be, for at least three (3) years after termination of this Agreement, or for such longer
                                         period as may be required by Applicable Law.

 

		4.5.2	Each
                                         Party shall have the right, during normal business hours and upon reasonable notice,
                                         to inspect and make copies of all records of the other Party that pertain to the subject
                                         matter of this Agreement and that are reasonably required by such Party, except, without
                                         limitation, for files that cannot be shared due to applicable privacy regulations or
                                         that are subject to the attorney-client privilege. The inspecting Party shall maintain
                                         such records and the information disclosed therein in accordance with the confidentiality
                                         clauses of Clause 9 of this Agreement.

 

		4.5.3	Without
                                         prejudice to the provisions of Clause 2, the JSC shall determine what reports shall be
                                         generated to track the EAP activities, including the content and timing thereof. 

 

			5   – Exclusive distribution,
                                         supply and manufacture 

 

		5.1	Distribution.

 

HEMISPHERX hereby appoints IMPATIENTS
as its sole and exclusive distributor in respect of EAP use of Product for use in the Field in the Territory, limited to EAP use
of Product in accordance with Early Access Approvals.

 

		5.2	Product Supply.

 

		5.2.1	HEMISPHERX undertakes and agrees
                                         to supply to IMPATIENTS on an exclusive basis, IMPATIENTS’
                                         requirements of Product ordered in accordance with the terms of this Agreement, for distribution
                                         and sale in the Territory, limited to EAP use of Product in accordance with Early Access
                                         Approvals.

 

		5.2.2	IMPATIENTS
                                         undertakes and agrees to obtain its requirements of Product for use in the Field
                                         from HEMISPHERX in accordance with the terms of this Agreement.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	10

     

    

 

		5.3	Product Manufacturing.

 

		5.3.1	Manufacturing.

 

HEMISPHERX shall solely be
responsible for the manufacturing, fill & finish, labeling and, if applicable, stockpiling of cGMP grade Product in compliance
with the Quality Agreement attached as Exhibit 5, and shall exert its reasonable commercial best efforts to provide quantities
of cGMP Product sufficient to meet the requirements of the EAP. If HEMISPHERX contracts the manufacturing and/or filling and/or
finishing and/or labeling and/or stockpiling of Product to a third party, such third party shall be considered a Manufacturer.
HEMISPHERX will ensure that all relevant obligations deriving from this Agreement (including the Quality Agreement) between Parties
are part of the contractual relationship between HEMISPHERX and any Manufacturer. HEMISPHERX shall provide all required documentation
to IMPATIENTS related to the manufacturing for purposes of furthering the activities of the EAP.

 

		5.3.2	Interruption of Supply.

 

If HEMISPHERX is unable to
meet IMPATIENTS’ requirements for Product, HEMISPHERX will notify IMPATIENTS and the JSC will meet as soon as possible to
negotiate a possible resolution.

 

			6   - Supply of Product and Invoicing

 

		6.1	Notification of Requirements.

 

IMPATIENTS shall notify HEMISPHERX
of its estimated Product requirements for the following {***} months {***}  days before the start of {***}
(“Rolling Forecast”). Said estimate shall not constitute a firm commitment by IMPATIENTS. HEMISPHERX shall, within
10 business days of receipt of such Rolling Forecast, indicate to IMPATIENTS if it agrees to such Rolling Forecast. The enrollment
of patients into the EAP and the Rolling Forecast shall be mutually agreed between the Parties.

 

		6.2	Available Stock.

 

HEMISPHERX shall use its best
efforts to ensure that sufficient quantities of Product for 6 months of treatment for all patients then enrolled in the EAP are
in stock at the warehouse of IMPATIENTS’s logistics service provider (“LSP”). In addition, HEMISPHERX shall
use reasonable commercial efforts to ensure that sufficient quantities of Product for the following six months projected sales,
based on the most recent Rolling Forecast, as agreed in accordance with Clause 6.1, are in stock at the warehouse of IMPATIENTS’
LSP. The legal ownership of the stock in the warehouse of IMPATIENTS’ LSP (further referred to as “Consignment Stock”)
shall remain with HEMISPHERX and will at no time be transferred to IMPATIENTS or the LSP. At the time of IMPATIENTS’ delivery
of the Product through its LSP to its clients, legal ownership of the Product will directly transfer from HEMISPHERX to the relevant
client of IMPATIENTS. Any costs related to the keeping Consignment Stock shall be at the expense of IMPATIENTS.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	11

     

    

 

		6.3	Product Shipment.

 

HEMISPHERX shall deliver the
Product DDP (INCOTERMS 2010) at the Consignment Stock warehouse address of IMPATIENTS’ LSP. At the warehouse of IMPATIENTS’
LSP, Product will be made ready for delivery to IMPATIENTS’ clients, in a manner controlled by IMPATIENTS and in accordance
with the Quality Agreement.

 

		6.4	Shipment Authorization.

 

HEMISPHERX hereby authorizes
IMPATIENTS to order its LSP to use Product from the Consignment Stock for the fulfilling of orders from IMPATIENTS’ clients
without further approval from HEMISPHERX. HEMISPHERX shall make sure the Consignment Stock is replenished in a timely manner to
comply with the stock level requirement as mentioned in Clause 6.2.

 

		6.5	Invoice.

 

IMPATIENTS shall notify HEMISPHERX
at the beginning of {***} of all fulfilled Product orders and Net EAP Sales (in Euros (€)) of Product from the preceding
{***}. HEMISPHERX shall send IMPATIENTS an invoice in Euros (€) for 65% of Net EAP Sales in such {***} and
IMPATIENTS shall pay the amount of such invoice to HEMISPHERX in Euros (€) within {***} days of receipt.

 

		6.6	Product Pricing.

 

The Price of the Product is specified
in Exhibit 4. Prices are stated excluding VAT or other taxes or levies.

 

			7   – Compensation to IMPATIENTS
                                         for agreed services

 

		7.1	Royalty Obligation.

 

		7.1.1.1	During the EAP, IMPATIENTS
                                         shall, to the extent permitted by Applicable Law, collect information and data, including
                                         but not limited to patient-reported outcomes, doctor-reported experiences and registry
                                         data, and shall provide support services useful for Marketing Authorization applications
                                         in the Territory. As a compensation for the collection of such information and data,
                                         and/or the performance of such services, HEMISPHERX will pay to IMPATIENTS a royalty
                                         as further provided in this Clause 7.1.

 

		7.1.1.2	In
                                         the event that HEMISPHERX or any of its Affiliates receives Marketing Authorization in
                                         the Field for the Product in any country in the Territory, then HEMISPHERX shall pay
                                         IMPATIENTS (or its successors or assigns) a royalty of up to a maximum of {***}%
                                         of Net Sales of Product in the countries in the Territory for which Marketing Authorization
                                         is granted. In the event that {***} patients
                                         are entered into the EAP, such royalty percentage shall be calculated in accordance with
                                         the following formula:

 

{***}

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	12

     

    

 

Exhibit
7 sets out a number of worked examples for this calculation.

 

		7.1.2	Royalties
                                         payable in respect of Net Sales shall be payable on a {***}
                                         basis for a period starting from the receipt of Marketing Authorization and ending the
                                         date{***} years from the {***}
                                         of such Product {***}.

 

		7.1.3	HEMISPHERX shall not be entitled
                                         to assign, sell or dispose of its rights in respect of the Product in the Field to a
                                         third party (including granting a third party the right to file for a Marketing Authorization
                                         based on HEMISPHERX’s rights and know how) unless such third party undertakes in
                                         writing to IMPATIENTS to be bound by the provisions of this Clause 7 as if such third
                                         party were a party to this Clause 7 instead of HEMISPHERX. For the avoidance of doubt,
                                         by third party in this Clause 7 is meant any person or entity that is not a Party to
                                         this agreement, including any Affiliate of HEMISPHERX.

 

		7.1.4	For
                                         the purposes of the calculation of the royalty payment under this Clause 7.1, Product
                                         Net Sales shall be reported, and royalties based on such Product Net Sales shall be paid,
                                         to IMPATIENTS within {***} after the end
                                         of each {***}
                                         during which Product has been sold. HEMISPHERX,
                                         its Affiliates, licensees, successors and/or assigns shall maintain accurate records
                                         of Product sales for a period of no less than seven years. Such records may be audited
                                         for accuracy once a year by an independent public accounting firm, acceptable to both
                                         Parties, which accounting firm would be allowed reasonable access at reasonable times
                                         to review all relevant records.

 

			8   – Warranties and Undertakings,
                                         Liability and Indemnity

 

		8.1	Mutual Representations and Warranties.

 

The Parties
represent and warrant and, where relevant, undertake to each other, as of the Effective Date, as follows:

 

		8.1.1	Organization.
                                         

 

It
is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization,
and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.

 

		8.1.2	Authorization.
                                         

 

The
execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized
by all necessary corporate action, and do not violate (a) such Party’s charter documents, bylaws, articles of association
or other organizational documents, (b) any material respect, any agreement, instrument, or contractual obligation to which such
Party is bound, (c) any requirement of any Applicable Law, or (d) any order, writ, judgment, injunction, decree, determination,
or award of any court or governmental agency presently in effect applicable to such Party.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

 

    	 	 	13

     

    

 

 

		8.1.3	Binding
                                         Agreement. 

 

This
Agreement is a legal, valid, and binding obligation of such Party, enforceable against it in accordance with its terms and conditions,
subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights,
judicial principles affecting the availability of specific performance, and general principles of equity (whether enforceability
is considered a proceeding at law or equity).

 

		8.1.4	No
                                         Inconsistent Obligation. 

 

It
is not under any obligation, contractual or otherwise, to any person that conflicts with or is inconsistent in any material respect
with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder.

 

		8.2	Product Warranty and Undertaking.

 

HEMISPHERX warrants and undertakes
that all Product supplied to IMPATIENTS under this Agreement shall comply with the Specifications; be manufactured, filled, finished,
labeled and packed in GMP facilities and in accordance with the Quality Agreement and all Applicable Laws; be free from contamination
or adulteration; be adequately packed to withstand transportation. At the time of delivery, each Product shall have no less than
9 (nine) months of the Product’s registered shelf life remaining.

 

		8.3	Product Liability.

 

HEMISPHERX represents and warrants
to IMPATIENTS that HEMISPHERX is legally bound to retain responsibility and liability for the manufacture of the Product at all
times and undertakes that it shall maintain product and general liability insurance covering any loss, costs, expenses, liability,
actions, demands, claims or proceedings relating to the Product.

 

		8.4	Indemnity.
                                         

 

Each Party shall indemnify and
hold the other Party harmless from any claims, suits, demands, judgments, actions, liabilities, (including strict liability and
infringement of a third party’s patent rights) expenses (including reasonable attorney’s fees) and damages relating
to the Product and caused directly or indirectly by any act or omission of the other Party and its officers, directors,
employees, subcontractors, agents or suppliers, or (in the case of HEMISPHERX only) the Manufacturer. This indemnity shall
not apply if any such liability, loss, damage, cost or expense is due to the gross negligence or default in performance by the
indemnified Party, its officers, directors, employees, subcontractors, agents or suppliers.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	14

     

    

 

		8.5	Waiver
                                         of consequential or punitive damages.

 

Save as for intentional wrongdoing
by a Party, neither Party, nor any of their respective directors, officers, employees or agents shall have any liability towards
the other Party, for any indirect or consequential damages claimed by the other Party, including, but not limited to the loss
of opportunity, loss of use, and/or loss of revenue or profit, in connection with or arising out of this Agreement or breach thereof.

 

		8.6	Insurance

 

Each Party shall maintain at its
own cost at all times during the term of this Agreement, policies of insurance in such amounts and to cover such risks as are
reasonable, prudent and/or potentially foreseeable hereunder. Maintenance of such insurance coverage will not relieve a Party
of any responsibility under this Agreement for damages in excess of insurance limits or otherwise.

 

			9   - Confidentiality

 

		9.1	The Parties will continue to abide
                                         by the confidentiality agreement signed by both Parties dated 11 June 2015, provided
                                         that the term of the confidentiality agreement shall be extended as long as necessary
                                         so as not to expire before the expiration or termination of this Agreement. The
                                         terms of confidentiality respecting Information shall not impede the appropriate use
                                         thereof in IMPATIENTS’s submission of Information in Early Access Approvals applications
                                         with Regulatory Authorities, in HEMISPHERX’s submission of Information in Marketing
                                         Authorization Applications with Regulatory Authorities, or in execution of the EAP of
                                         Product according to the EAP Plan.

 

		9.2	HEMISPHERX acknowledges that the EAP
                                         Plan involves the publication of safety and efficacy information relating to the Product,
                                         including HEMISPHERX Confidential Information included in the Regulatory Documentation,
                                         and the patient- and doctor-reported outcomes and registry data generated and collected
                                         during the performance of the EAP. Therefore, HEMISPHERX hereby consents to IMPATIENTS
                                         publishing such HEMISPHERX’s Confidential Information as is required in accordance
                                         with Applicable Laws.

 

		9.3	HEMISPHERX and IMPATIENTS agree to
                                         use all Confidential Information received under this Agreement solely for the purpose
                                         set forth herein and agree not to otherwise interfere in the business of the other in
                                         any respect.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	15

     

    

 

			10   - Duration, termination

 

		10.1	This
                                         Agreement will become legally effective on the Effective Date and, unless earlier terminated
                                         pursuant to the terms hereof, shall continue in full force and effect for an initial
                                         period of {***} years. This initial period
                                         may be extended upon mutual written agreement between the Parties and in the absence
                                         of a notice to the other Party (to be given with at least 90 days notice) from a Party
                                         that it does not agree to the extension of this Agreement under this Clause 10.1, shall
                                         be extended each anniversary by 12 months until commercial availability of the Product
                                         in the Territory following receipt by HEMISPHERIX or one of its Affiliates of appropriate
                                         Marketing Authorization. 

 

		10.2	Subject to any mandatory provision
                                         of law, this Agreement may be terminated by a Party, without any liability to the other,
                                         if the other Party is dissolved or liquidated, files or has filed against it a petition
                                         under any applicable bankruptcy or insolvency law, makes a general assignment for the
                                         benefit of its creditors, or has a receiver appointed for substantially all of its assets.

 

		10.3	Following
                                         expiry of the initial {***}-year term as
                                         set out in Clause 10.1, either Party may terminate this Agreement, provided the non-terminating
                                         Party is provided with 6 (six) months written notification.

 

		10.4	HEMISPHERX shall have the right to
                                         terminate this agreement at any time during the Term provided that it shall provide IMPATIENTS
                                         with ninety (90) days written notification.

 

		10.5	In the event that HEMISPHERX does
                                         not provide notification of ability to supply the Product for the EAP under Clause 6.2
                                         within twelve (12) months of the Effective Date, IMPATIENTS shall be entitled to terminate
                                         this Agreement with thirty (30) days written notification.

 

		10.6	Each Party reserves the right to immediately
                                         terminate this Agreement if the other Party is in breach of its material obligations
                                         under this Agreement and fails to remedy such breach within 6 (six) months written notification
                                         by the other Party of said breach. In the event of a breach not being capable of remedy
                                         within 6 (six) months of written notification, the parties shall negotiate in good faith
                                         to agree a period for remedy after which, if the breach remains, the Party whose obligations
                                         are not in such continuing breach shall be entitled to terminate this Agreement.

 

		10.7	Consequences of Termination.

 

		10.7.1	In the event of a termination of
                                         this Agreement under Clauses 10.1 to 10.5 (inclusive), HEMISPHERX shall permit IMPATIENTS
                                         to continue to distribute and sell the Product until such time that the entire quantity
                                         of the Consignment Stock has been sold.

 

		10.7.2	In
                                         the event of termination of this Agreement pursuant to Clause 10.1, termination by HEMISPHERX
                                         pursuant to Clause 10.3 or by IMPATIENTS pursuant to Clause 10.5, Clause 7.1 shall
                                         survive such termination and the royalty rate to be applied to Net Sales of Product shall
                                         be the percentage as calculated in accordance with such Clause 7.1{***}.

 

		10.7.3	In the event of termination of this
                                         Agreement by HEMISPHERX pursuant to Clause 10.4, Clause 7.1 shall survive such termination
                                         and the royalty rate to be applied to Net Sales of Product shall be set according to
                                         the Termination Algorithm outlined in Exhibit 7.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	16

     

    

 

		10.7.4	Upon termination of this Agreement
                                         by IMPATIENTS pursuant to Clause 10.3 or by HEMISPHERX pursuant to Clauses 10.5 or 10.6,
                                         Clause 7.1 shall not survive termination and no royalty shall be payable to IMPATIENTS
                                         under such provision.

 

		10.8	Survival.

 

In addition to and subject to
the provisions of Clause 10.6, Clause 1, Clauses 4.5.1 and 4.5.2, Clause 6.5 and Clauses 8 to 11 shall survive termination of
this Agreement.

 

			11   – Miscellaneous

 

		11.1	Entire Agreement.

 

This Agreement, together with
the Confidentiality Agreement dated 11 June 2015 and signed by the Parties prior to the Effective Date, constitutes the entire
agreement between the Parties as regards the Product, and any former agreement relating to the same subject matter hereby becomes
null and void. In the event of any inconsistencies between the terms of these Agreements, the terms of this Agreement shall prevail.

 

		11.2	Amendments.

 

Modifications to this Agreement
shall be made in writing only, and shall only take effect when signed by both Parties.

 

		11.3	Press releases

 

Each Party shall have the right
to disclose the existence of this Agreement, but not any of its material terms (which shall remain Confidential Information of
both Parties), provided that such disclosing Party shall provide to the other Party the proposed text of any press release for
review not less than five (5) days prior to public disclosure.

 

		11.4	Independent Contractors.

 

It is understood that both Parties
hereto are independent contractors and engage in the operation of their own respective businesses. Neither Party hereto is to
be considered the agent of the other Party for any purpose whatsoever, and neither Party has any authority to enter into any contract
or assume any obligation for the other Party or to make any warranty or representation on behalf of the other Party. Each Party
shall be fully responsible for its own employees, servants and agents, and the employees, servants and agents of one Party shall
not be deemed to be employees, servants and agents of the other Party for any purpose whatsoever.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	17

     

    

 

		11.5	Remedy; Waiver.

 

Exercise by any Party of any
of its rights under this Agreement shall not be deemed to limit any other right or remedy that such Party may have in law or equity.
The waiver by either Party of a breach of any of the provisions of this Agreement by the other Party shall not be construed as
a waiver of any succeeding breach of the same or other provisions, nor shall any delay or omission by either Party in exercising
any right that it may have under this Agreement operate as a waiver of any breach or default by the other Party.

 

		11.6	Formalities.

 

Each Party agrees to execute
deliver and/or do such further papers, agreements or acts as may be necessary or desirable to give effect to this Agreement and
its purpose and to carry out its provisions.

 

		11.7	Choice of Law and Dispute
                                         Resolution.

 

This Agreement shall be governed
by and interpreted under the laws of the Netherlands. All disputes arising out of or in connection with this Agreement shall be
submitted to the International Court of Arbitration of the International Chamber of Commerce and shall be finally settled under
the Rules of Arbitration of the International Chamber of Commerce by three arbitrators appointed in accordance with the said Rules.
Any such arbitration shall take place in Amsterdam, the Netherlands and in the English language.

 

		11.8	Language.

 

This Agreement is executed in
the English language. The language used in this Agreement shall be deemed to be the language chosen by the Parties hereto to express
their mutual intent and no rule of strict construction against either Party shall apply to any term or condition of this Agreement.
The definitive language of this Agreement is English and no reliance shall be placed upon any translation into any other language.

 

		11.9	Assignment; Assumption.

 

Subject to the provisions of
Clause 7.1.3, neither this Agreement nor any rights or obligations hereunder may be assigned or duties delegated (other than specified
in the EAP Plan) by either Party without the prior written consent of the other Party, which consent shall not be unreasonably
withheld. Any assignment in violation of this clause shall be null and void. Any permitted assignee shall, upon the request of
the other Party hereto, expressly acknowledge, by written agreement, its assumption of all obligations and liabilities under this
Agreement.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	18

     

    

 

		11.10	Force Majeure.

 

Should a Party be unable to perform
any of its obligations under this Agreement due to an event of force majeure as determined by law such Party shall be excused
to perform its obligation during the period of such force majeure event provided always that it gives the other Party prompt written
notice of such force majeure event. If the event of force majeure were to prevent such Party performing its obligations in connection
with this Agreement for a continuous period of more than three (3) months, the other Party may terminate the Agreement at its
sole option by giving written notice thereof, without any indemnity to be paid by either Party. The termination would then take
effect without further notice, at the date of receipt of the above notice. In no event shall this provision relieve either Party
of its obligation to make payment when owing.

 

		11.11	Severability.

 

If any provision of this Agreement
is found to be invalid or unenforceable by any court or administrative body of competent jurisdiction, then the invalidity or
unenforceability of such provision shall not affect the other provisions of this Agreement, and all provisions not affected by
such invalidity or unenforceability shall remain in full force and effect. The Parties agree to attempt to substitute for any
invalid or unenforceable provision a valid or enforceable provision, which achieves to the greatest extent possible the economic
objectives of the invalid or unenforceable provision. If any provision of this Agreement conflicts with applicable legislation,
then the Parties shall modify such provision in order to comply with said legislation. This modification shall not affect the
other provisions of this Agreement.

 

		11.12	Notice.

 

All formal notices to be given
pursuant to this Agreement shall be in writing and in English and shall be delivered by hand, sent by registered mail return receipt,
or by express courier service to the address of the Party to receive such notice as set out below (or such other address as may
be notified by a Party to the other from time to time). Notices shall be deemed to have been received at the time of delivery
by hand, at the date affixed on the return receipt or 3 (three) business days after sending if sent by express courier service.

 

	For
    HEMISPHERX:	For
    IMPATIENTS:
	 	 
	HEMISPHERX:	Impatients N.V.:
	Attn: Thomas Equels	Attn.: {***}
	1617 JFK Boulevard	Pilotenstraat 45
	Suite 500	1059 CH
	Philadelphia, Pa. 19013	Amsterdam
	 	The Netherlands
	 	Email:
    {***}

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	19

     

    

 

		11.13	Construction. 

 

Except where the context otherwise
requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable
to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number
of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of
reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision
contained in this Agreement. The term “including,” “include,” or “includes” as used herein
shall mean “including, but not limited to,” and shall not limit the generality of any description preceding such term.
The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction
shall be applied against either Party hereto. Each Party represents that it has been represented by legal counsel in connection
with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and
provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and
provisions.

 

IN WITNESS WHEREOF, the Parties
have executed this Agreement by their respective, duly authorized, representatives:

 

	For
    HEMISPHERX: 	 	For
    IMPATIENTS:
	 	 	 
	s/Thomas Equels	 	s/Ronald Brus
	Thomas Equels	 	Ronald
    Brus
	CEO	 	CEO

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	20

     

    

 

Exhibit 1. – EAP Plan 

 

(to be inserted after being agreed by
JSC)

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

 

    	 	 	21

     

    

 

Exhibit 2 – JSC and subcommittees

 

		1	JSC.

 

		1.1	Composition.

 

The
JSC shall consist of{***}, each with the requisite experience and seniority to enable
such person to make decisions on behalf of a Party with respect to the issues falling within the jurisdiction of the JSC. From
time to time, each Party may substitute one or more of its representatives to the JSC on written notice to the other Party. {***}.
The chairperson shall appoint a secretary of the Joint Steering Committee, who shall be {***}.

 

		1.2	Specific Responsibilities.

 

The JSC shall oversee the EAP
for the Product in the Territory, and shall serve as a forum for the coordination of activities for the Product for the Territory.
In particular, the JSC shall:

 

		(a)	periodically
                                         (no less often than annually) review and serve as a forum for discussing the EAP, and
                                         review and approve amendments thereto;

		(b)	oversee
                                         the conduct of EAP activities;

		(c)	serve
                                         as a forum for discussing and coordinating strategies for obtaining Early Access Approvals
                                         and Regulatory Approvals for the Product in the Territory;

		(d)	establish
                                         secure access methods (such as secure databases) for each Party to access Regulatory
                                         Documentation and other JSC related Information as contemplated under this Agreement;
                                         and

		(e)	perform
                                         such other functions as are set forth herein or as the Parties may mutually agree in
                                         writing, except where in conflict with any provision of this Agreement.

		(f)	Approve
                                         HEMISPHERX Know-How and Regulatory Documentation to be shared with Regulatory Authorities
                                         and physicians both under relevant confidentiality mechanisms.

 

		1.3	Disbandment.
                                         

 

Upon
Marketing Authorization of the Product in all countries of the Territory, unless otherwise mutually agreed in writing, the JSC
shall have no further responsibilities or authority under this Agreement and will be considered dissolved by the Parties. 

 

		1.4	Subcommittees.
                                         

 

From
time to time, the JSC may establish and delegate duties to sub-committees or directed teams (“Subcommittees(s)”) on
an “as-needed” basis to oversee particular projects or activities (for example, joint project team, joint finance
group, and/or joint intellectual property group). Each such Subcommittee shall be constituted and shall operate as the JSC determines;
provided that each Subcommittee shall have equal representation from each Party, unless otherwise mutually agreed. Subcommittees
may be established on an ad hoc basis for purposes of a specific project or on such other basis as the JSC may determine.
Each Subcommittee and its activities shall be subject to the oversight, review and approval of, and shall report to, the JSC.
In no event shall the authority of the Subcommittee exceed that specified for the JSC. All decisions of a Subcommittee shall be
by unanimous agreement.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	22

     

    

 

		2	General Provisions Applicable to committees.

 

		2.1	Meetings and Minutes.

 

The committees shall meet quarterly
by telephonic or tele video means, or, when necessary as agreed between the Parties, face-to-face, with the location of such face-to-face
meetings alternating between locations designated by HEMISPHERX and locations designated by IMPATIENTS. The chairperson of the
applicable committee shall be responsible for calling meetings on no less than thirty (30) Business Days’ notice. Each Party
shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items at
least ten (10) Business Days in advance of the applicable meeting; provided that under exigent circumstances requiring
input by the committee, a Party may provide its agenda items to the other Party within a shorter period of time in advance of
the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as the other Party consents
to such later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably
withheld or delayed. The chairperson of the committee shall prepare and circulate for review and approval of the Parties minutes
of each meeting within thirty (30) days after the meeting. The Parties shall agree on the minutes of each meeting promptly, but
in no event later than the next meeting of the committee. If the Parties cannot agree on the content of the minutes the objecting
party shall append a notice of objection with the specific details of the objection to the proposed minutes.

 

		2.2	Procedural Rules.

 

Each committee shall have the
right to adopt such standing rules as shall be necessary for its work, to the extent that such rules are not inconsistent with
this Agreement. A quorum of the committee shall exist whenever there is present at a meeting at least one (1) representative appointed
by each Party. Representatives of the Parties on a committee may attend a meeting either in person or by telephone, video conference
or similar means in which each participant can hear what is said by, and be heard by, the other participants. Representation by
proxy shall be allowed. Each committee shall take action by unanimous agreement of the representatives present at a meeting at
which a quorum exists, with each Party having a single vote irrespective of the number of representatives of such Party in attendance,
or by a written resolution signed by at least one (1) representative appointed by each Party. Employees or consultants of either
Party that are not representatives of the Parties on a Committee may attend meetings of such committee; provided, however,
that such attendees (a) shall not vote or otherwise participate in the decision-making process of the Committee, and (b) are
bound by obligations of confidentiality and non-disclosure equivalent to those set forth in Section 11.1 of the Agreement.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	23

     

    

 

		2.3	Committee Dispute Resolution.

 

If a subcommittee cannot, or
does not, reach unanimous agreement on an issue at a meeting or within a period of ten (10) Business Days thereafter or such other
period as the Parties may agree, then the dispute shall be referred to the JSC for resolution and a special meeting of the JSC
may be called for such purpose. If the JSC cannot, or does not, reach unanimous agreement on an issue, including any dispute arising
from the JSC, then the dispute shall first be referred to the senior officers of the Parties, who shall confer in good faith on
the resolution of the issue. Any final decision mutually agreed to by the senior officers shall be conclusive and binding on the
Parties.

 

		2.4	Limitations on Authority.

 

Each Party shall retain the
rights, powers, and discretion granted to it under this Agreement and no such rights, powers, or discretion shall be delegated
to or vested in a committee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties
expressly so agree in writing. No committee shall have the power to amend, modify, or waive compliance with this Agreement, which
may only be amended or modified as provided in Section 11.2 of the Agreement.

 

		2.5	Alliance Manager.

 

Each Party shall appoint a person(s)
who shall oversee contact between the Parties for all matters between meetings of each committee and shall have such other responsibilities
as the Parties may agree in writing after the Effective Date (each, an “Alliance Manager”). Each Party may replace
its Alliance Manager at any time by notice in writing to the other Party.

 

		3	Discontinuation of Participation on
                                         a Committee.

 

Each committee shall continue
to exist until the first to occur of: (i) the Parties mutually agreeing to disband the committee; or (ii) upon receipt
of Marketing Authorization of the Product in the last country of the Territory.

 

		4	Expenses.

 

Each Party shall be responsible
for all travel and related costs and expenses for its members and other representatives to attend meetings of, and otherwise participate
on, a committee.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

 

    	 	 	24

     

    

 

Exhibit 3 – Trademark usage conditions

 

		1.	Product Trademark License Terms.

 

		1.1.	IMPATIENTS acknowledges HEMISPHERX’s
                                         exclusive right, title, and interest in and to the Product Trademarks and acknowledges
                                         that (i) neither this Agreement, nor its use of the Product Trademarks hereunder, shall
                                         be construed to accord to IMPATIENTS any rights in the Product Trademarks other than
                                         the limited license rights granted herein, and (ii) the goodwill generated thereby will
                                         inure solely and entirely to the benefit of HEMISPHERX.

 

		1.2.	Should it be necessary to record
                                         IMPATIENTS as a registered licensee of the Product Trademarks in any jurisdiction, HEMISPHERX
                                         shall do so at IMPATIENTS's expense, and IMPATIENTS will cooperate with HEMISPHERX to
                                         effect such recordation.

 

		2.	Trademark Use.

 

IMPATIENTS may use the Product
Trademarks solely in conjunction with the Product EAP.

 

		2.1.	Product Trademarks Usage Requirements.

 

IMPATIENTS agrees to comply
with the Product Trademarks usage requirements of this Exhibit 2.1.

 

		2.2.	The Product Trademarks may not
                                         be used in connection with the display, advertising, or promotion of Product for any
                                         purpose IMPATIENTS has not been appointed for.

 

		2.3.	The Product Trademarks may not
                                         to be altered. The Product Trademarks are not to be used in conjunction with any other
                                         mark or design, i.e., the Product Trademarks must stand alone in terms of the commercial
                                         impression generated by the particular usage; provided, however, that IMPATIENTS’s
                                         trademarks may be used along with the Product Trademarks as long as such trademarks do
                                         not combine, superimpose or overlap with the Product Trademarks.

 

		2.4.	IMPATIENTS must exercise care
                                         in the use of the Product Trademarks so as not to indicate to the public that IMPATIENTS
                                         is a division or affiliate of HEMISPHERX or otherwise related to HEMISPHERX.

 

		2.5.	IMPATIENTS shall not use as its
                                         own trademark any word(s) or design(s) confusingly similar to the Product Trademarks.

 

		3.	Protection of Interest.

 

If IMPATIENTS becomes aware of any unauthorized
use of the Product Trademarks by a third party, IMPATIENTS, subject to its confidentiality obligations to other parties, agrees
to promptly notify HEMISPHERX and to cooperate fully, at HEMISPHERX's expense, in the enforcement of HEMISPHERX's rights against
such a third party. Nothing contained in this Section shall be construed as to require HEMISPHERX to enforce any rights against
a third party or to restrict HEMISPHERX's rights to license or consent to such a third party's use of the Product Trademarks.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	25

     

    

 

Exhibit 4 – Price of Product

 

Product Price to be invoiced by IMPATIENTS
to third parties (excluding VAT):

 

USD {***}
for a {***} course of treatment of {***}
vials {***}. Meaning{***}
vials in total, with an equivalent price of USD {***} per vial 

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	26

     

    

 

Exhibit 5 - Quality Agreement

 

(to be inserted after being agreed by
JSC)

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

    	 	 	27

     

    

 

Exhibit 6 -Pharmacovigilance
Agreement

 

(to be inserted after being agreed by
JSC)

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

    	 	 	28

     

    

 

Exhibit 7 –Royalty
Payment Example Calculations

 

For the purposes of illustration of the calculation
of the royalty payments under Clause 7.1, the formula(s) would be calculated in the following situations as follows:

 

{***}

 

This demonstrates
that if, during the course of the EAP, {***} patients have been admitted to the EAP
the maximum royalty percentage will have been reached.

 

In the event of termination of this Agreement
by HEMISPHERX pursuant to Clause 10.4, Clause 7.1 shall survive such termination and the royalty rate to be applied to Net Sales
of Product shall be set according to the following Termination Algorithm:

 

If Hemispherx terminates without cause:

 

Royalty Rate on Hemispherx Commerical
Sales As a Function of EAP Performance and Time

 

Cumulative EAP Patients    >6
mos <1 year    >1 yr <2 yrs    >2 yrs <3yrs    >3
yrs <4 yrs    >4 yrs <5 yrs

 

{***}

 

For the
avoidance of doubt, where the Termination Algorithm matrix above provides that, on termination by Hemispherx in accordance with
clause 10.4, the royalty rate shall be calculated in accordance with the formula, then such formula shall be the formula set out
in Clause 7.1 {***}.

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

    	 	 	29

     

    

 

Exhibit 8 –List
of Deductions

 

Trade discounts or rebates, mutually agreed
between the Parties

 

Amounts reserved for claims, allowances or
credits connected with rejections or returns of Product

 

Packaging, handling fees and costs of
freight, insurance, sales taxes duties and other governmental charges (which sums shall include value added tax and its equivalents,
but shall not include income taxes)

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

 

    	 	 	30

     

    

Exhibit 9 – Data
to be collected

 

To the extent permitted by Applicable
Law, IMPATIENTS shall use it reasonable commercial efforts to collect the following data in relation to the EAP:

 

		1)	Patient completed SF-36 questionnaire
                                         and Karnofsky Performance questionnaire every 8 weeks

 

		2)	Physician’s Karnofsky performance
                                         score (based on patient questionnaire) every 8 weeks.

 

		3)	Physician completed
                                         Chronic Fatigue Syndrome questionnaire

 

		4)	Safety / adverse
                                         events in accordance with the Pharmacovigilance Agreement

 

{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

    	 	 	31EX-10.2

 Exhibit 10.2 

ANAPTYSBIO, INC. 
 2006
EQUITY INCENTIVE PLAN 
 ADOPTED BY THE BOARD: APRIL 24, 2006 

APPROVED BY THE STOCKHOLDERS: MAY 26, 2006 

AMENDED BY THE BOARD: MARCH 19, 2007 

APPROVED BY THE STOCKHOLDERS: MAY 18, 2007 

AMENDED BY THE BOARD: JUNE 28, 2007 

APPROVED BY THE STOCKHOLDERS: JUNE 28, 2007 

AMENDED BY THE BOARD: JULY 11, 2014 

APPROVED BY THE STOCKHOLDERS: APRIL 29, 2015 

AMENDED BY THE BOARD: JULY 9, 2015 

APPROVED BY THE STOCKHOLDERS: JULY 9, 2015 

AMENDED AND RESTATED BY THE BOARD TO EXTEND TERM: APRIL 22, 2016 

APPROVED BY THE STOCKHOLDERS: JANUARY 13, 2017 

TERMINATION DATE: APRIL 21, 2026 
  

	1.	GENERAL. 

 (a) Eligible Stock Award Recipients. The persons eligible to
receive Stock Awards are Employees, Directors, and Consultants.  
 (b) Available Stock Awards. The Plan provides for the grant
of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Restricted Stock Awards, and (iv) Stock Appreciation Rights. 

(c) Purpose. The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to receive
Stock Awards as set forth in Section 1(a), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and to provide a means by which such eligible recipients may be given an opportunity to
benefit from increases in value of the Common Stock through the granting of Stock Awards.  
  

	2.	DEFINITIONS. 

 As used in the Plan, the following definitions shall apply to the
capitalized terms indicated below: 
 (a) “Affiliate” means, at the time of
determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board shall have the authority to determine the time or times at which “parent” or
“subsidiary” status is determined within the foregoing definition.  
 (b) “Board” means the Board
of Directors of the Company. 
 (c) “Capitalization Adjustment” has the meaning ascribed to that term in Section 10(a).

 (d) “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one
or more of the following events: 
 (i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the
Company representing more than fifty percent (50%) of the combined voting power of the Company’s 

  
 1 

 
then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on
account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of
which is to obtain financing for the Company through the issuance of equity securities or (B) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of
the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this
sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not
occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; 

(ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately
after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than fifty
percent (50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the
surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; or 

(iii) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets
of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of the combined
voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or
other disposition. 
 The term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for
the purpose of changing the domicile of the Company. 
 Notwithstanding the foregoing or any other provision of this Plan, the definition of Change
in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Stock Awards subject to such agreement; provided, however,
that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.  

(e) “Code” means the Internal Revenue Code of 1986, as amended. 

(f) “Committee” means a committee of one or more Directors to whom authority has
been delegated by the Board in accordance with Section 3(c).  
 (g) “Common Stock” means
the common stock of the Company. 
 (h) “Company” means AnaptysBio, Inc., a Delaware corporation. 

  
 2 

 (i) “Consultant” means any person,
including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the Board of Directors of an Affiliate and is
compensated for such services. However, service solely as a Director, or payment of a fee for such service, shall not cause a Director to be considered a “Consultant” for purposes of the Plan.  

(j) “Continuous Service” means that the Participant’s service with the Company
or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in
the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, shall not terminate a Participant’s Continuous Service;
provided, however, if the corporation for which a Participant is rendering service ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service
shall be considered to have terminated on the date such corporation ceases to qualify as an Affiliate. For example, a change in status from an employee of the Company to a consultant of an Affiliate or to a Director shall not constitute an
interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case
of any leave of absence approved by that party, including sick leave, military leave or any other personal leave. Notwithstanding the foregoing, a leave of absence shall be treated as Continuous Service for purposes of vesting in a Stock Award only
to such extent as may be provided in the Company’s leave of absence policy or in the written terms of the Participant’s leave of absence.  

(k) “Corporate Transaction” means the occurrence, in a single transaction or in a
series of related transactions, of any one or more of the following events:  
 (i) a sale or other disposition of all
or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

(ii) a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company; 

(iii) the consummation of a merger, consolidation or similar transaction following which the Company is not the surviving corporation;
or 
 (iv) the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation
but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of
securities, cash or otherwise. 
 (l) “Director” means a member of the Board. 

(m) “Disability” means the inability of a Participant to engage in any substantially
gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months, and
shall be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.  

  
 3 

 (n) “Employee” means any person
employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, shall not cause a Director to be considered an “Employee” for purposes of the Plan.  

(o) “Entity” means a corporation, partnership, limited liability company, or other entity. 

(p) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(q) “Exchange Act Person” means any natural person, Entity or “group”
(within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” shall not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any
Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such
securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within
the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the effective date of the Plan as set forth in Section 13, is the Owner, directly or indirectly, of securities of the Company representing more than fifty percent
(50%) of the combined voting power of the Company’s then outstanding securities.  
 (r)
“Fair Market Value” means, as of any date, the value of the Common Stock determined by the Board and (i) in a manner consistent with Section 260.140.50 of Title 10 of the California Code of
Regulations, and (ii) in compliance with Section 409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code. 

(s) “Incentive Stock Option” means an Option that qualifies as an incentive stock
option within the meaning of Section 422 of the Code and the regulations promulgated thereunder.  
 (t)
“Nonstatutory Stock Option” means an Option that does not qualify as an Incentive Stock Option. 
 (u)
“Officer” means any person designated by the Company as an officer. 
 (v)
“Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.  

(w) “Option Agreement” means a written agreement between the Company and an
Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan.  

(x) “Optionholder” means a person to whom an Option is granted pursuant to the Plan
or, if applicable, such other person who holds an outstanding Option.  
 (y)
“Own,” “Owned,” “Owner,” “Ownership” A person or Entity shall be deemed to “Own,” to have “Owned,” to be the
“Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes
the power to vote or to direct the voting, with respect to such securities.  
 (z)
“Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.  

  
 4 

 (aa) “Plan” means this AnaptysBio, Inc. 2006 Equity
Incentive Plan, as amended and restated, and as further amended from time to time.  
 (bb)
“Restricted Stock Award” means an award of shares of Common Stock, which is granted pursuant to the terms and conditions of Section 7(a).  

(cc) “Restricted Stock Award Agreement” means a written agreement between the
Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award. Each Restricted Stock Award Agreement shall be subject to the terms and conditions of the Plan.  

(dd) “Securities Act” means the Securities Act of 1933, as amended. 

(ee) “Stock Appreciation Right” means a right to receive the appreciation on Common Stock, that is granted
pursuant to the terms and conditions of Section 7(b). 
 (ff) “Stock Appreciation Right
Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement shall be subject to the
terms and conditions of the Plan.  
 (gg) “Stock Award” means any
right granted under the Plan, including an Option, a Restricted Stock Award, and a Stock Appreciation Right. 

(hh) “Stock Award Agreement” means a written agreement between the Company and a
Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan. 

(ii) “Subsidiary” means, with respect to the Company, (i) any corporation of
which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of
such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%).  

(jj) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock
possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Affiliate.  
  

	3.	ADMINISTRATION.  

 (a) Administration by Board. The Board shall administer
the Plan unless and until the Board delegates administration of the Plan to a Committee, as provided in Section 3(c).  
 (b)
Powers of Board. The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan:  

(i) To determine from time to time (1) which of the persons eligible under the Plan shall be granted Stock Awards; (2) when
and how each Stock Award shall be granted; (3) what type or combination of types of Stock Award shall be granted; (4) the provisions of each Stock Award granted (which need not be identical), including the time or times when a person shall
be permitted to receive 

  
 5 

 
cash or Common Stock pursuant to a Stock Award; and (5) the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such person. 

(ii) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for
its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully
effective. 
 (iii) To accelerate the time at which a Stock Award may first be exercised or the time during which a Stock Award or any
part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Stock Award stating the time at which it may first be exercised or the time during which it will vest. 

(iv) To effect, at any time and from time to time, with the consent of any adversely affected Participant, (1) the reduction of the
exercise price of any outstanding Option or the strike price of any outstanding Stock Appreciation Right under the Plan; (2) the cancellation of any outstanding Option or Stock Appreciation Right under the Plan and the grant in substitution
therefor of (a) a new Option or Stock Appreciation Right under the Plan or another equity plan of the Company covering the same or a different number of shares of Common Stock, (b) a Restricted Stock Award, (c) cash, and/or
(d) other valuable consideration (as determined by the Board, in its sole discretion); or (3) any other action that is treated as a repricing under generally accepted accounting principles 

(v) To amend the Plan or a Stock Award as provided in Section 11. 

(vi) To terminate or suspend the Plan as provided in Section 12. 

(vii) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best
interests of the Company and that are not in conflict with the provisions of the Plan. 
 (viii) To adopt such procedures and
sub-plans as are necessary or appropriate to permit participation in the Plan by individuals who are foreign nationals or employed outside the United States. 

(c) Delegation to Committee. The Board may delegate some or all of the administration of the Plan to a Committee or Committees of the
Board. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not
inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the
powers previously delegated.  
 (d) Effect of Board’s Decision. All determinations, interpretations and constructions
made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.  

  
 6 

	4.	SHARES SUBJECT TO THE PLAN.  

 (a) Share Reserve. Subject to the provisions
of Section 10(a) relating to Capitalization Adjustments, the Common Stock that may be issued pursuant to Stock Awards shall not exceed in the aggregate 18,871,272 shares of Common Stock.  

(b) Reversion of Shares to the Share Reserve. If any Stock Award shall for any reason expire or otherwise terminate, in whole or in
part, without having been exercised in full, or if any shares of Common Stock issued to a Participant pursuant to a Stock Award are forfeited back to or repurchased by the Company because of or in connection with the failure to meet a contingency or
condition required to vest such shares in the Participant, the shares of Common Stock not acquired, such Stock Award or the shares of Common Stock forfeited or repurchased under such Stock Award shall revert to and again become available for
issuance under the Plan; provided, however, that subject to the provisions of Section 10(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued as Incentive
Stock Options shall be twice the number of shares reserved under the Plan at any particular time.  
 (c) Source of Shares. The
stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. 

(d) Share Reserve Limitation. To the extent required by Section 260.140.45 of Title 10 of the California Code of Regulations, the
total number of shares of Common Stock issuable upon exercise of all outstanding Options and the total number of shares of Common Stock provided for under any stock bonus or similar plan of the Company shall not exceed the applicable percentage as
calculated in accordance with the conditions and exclusions of Section 260.140.45 of Title 10 of the California Code of Regulations, based on the shares of Common Stock of the Company that are outstanding at the time the calculation is made.
 
  

	5.	ELIGIBILITY.  

 (a) Eligibility for Specific Stock Awards. Incentive Stock
Options may be granted only to Employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and (f) of the Code. Stock Awards other than Incentive Stock
Options may be granted to Employees, Directors and Consultants.  
 (b) Ten Percent Stockholders. 

(i) A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of such Option is at least one
hundred ten percent (110%) of the Fair Market Value of the Common Stock on the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant. 

(ii) A Ten Percent Stockholder shall not be granted a Nonstatutory Stock Option unless the exercise price of such Option is at least
(i) one hundred ten percent (110%) of the Fair Market Value of the Common Stock on the date of grant, or (ii) such lower percentage of the Fair Market Value of the Common Stock on the date of grant as is permitted by
Section 260.140.41 of Title 10 of the California Code of Regulations at the time of the grant of the Option. 
 (iii) A Ten
Percent Stockholder shall not be granted a Restricted Stock Award or Stock Appreciation Right (if such award could be settled in shares of Common Stock), unless the purchase price 

  
 7 

 
of the restricted stock is at least (i) one hundred percent (100%) of the Fair Market Value of the Common Stock on the date of grant, or (ii) such lower percentage of the Fair
Market Value of the Common Stock on the date of grant as is permitted by Section 260.140.42 of Title 10 of the California Code of Regulations at the time of the grant of the award. 

(c) Consultants. A Consultant shall not be eligible for the grant of a Stock Award if, at the time of grant, either the offer or the
sale of the Company’s securities to such Consultant is not exempt under Rule 701 of the Securities Act (“Rule 701”) because of the nature of the services that the Consultant is providing to the Company, because the Consultant is not a
natural person, or because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply with the
securities laws of all other relevant jurisdictions. 
  

	6.	OPTION PROVISIONS. 

 Each Option shall be in such form and shall contain
such terms and conditions as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or
certificates shall be issued for shares of Common Stock purchased on exercise of each type of Option. The provisions of separate Options need not be identical; provided, however, that each Option Agreement shall include (through incorporation
of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:  
 (a) Term.
Subject to the provisions of Section 5(b) regarding Ten Percent Stockholders, no Option shall be exercisable after the expiration of ten (10) years from the date of grant.  

(b) Exercise Price of an Incentive Stock Option. Subject to the provisions of Section 5(b) regarding Ten Percent Stockholders, the
exercise price of each Incentive Stock Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Incentive
Stock Option may be granted with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner consistent with the provisions of
Section 424(a) of the Code. 
 (c) Exercise Price of a Nonstatutory Stock Option. Subject to the provisions of Section 5(b)
regarding Ten Percent Stockholders, the exercise price of each Nonstatutory Stock Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted.
Notwithstanding the foregoing, a Nonstatutory Stock Option may be granted with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner
consistent with the provisions of Section 424(a) of the Code.  
 (d) Consideration. The purchase price of Common Stock
acquired pursuant to the exercise of an Option shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the
authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.
The methods of payment permitted by this Section 6(d) are:  
 (i) by cash or check; 

  
 8 

 (ii) pursuant to a program developed under Regulation T as promulgated by the Federal
Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; 

(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; 

(iv) by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued
upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, the Company shall accept a cash or other payment from the Participant to the extent of any
remaining balance of the aggregate exercise price not satisfied by such holding back of whole shares; provided, however, shares of Common Stock will no longer be outstanding under an Option and will not be exercisable thereafter to the extent
that (i) shares are used to pay the exercise price pursuant to the “net exercise,” (ii) shares are delivered to the Participant as a result of such exercise, and (iii) shares are withheld to satisfy tax withholding
obligations; 
 (v) according to a deferred payment or similar arrangement with the Optionholder; provided, however, that
interest shall compound at least annually and shall be charged at the minimum rate of interest necessary to avoid (i) the imputation of interest income to the Company and compensation income to the Optionholder under any applicable provisions
of the Code, and (ii) the classification of the Option as a liability for financial accounting purposes; or 
 (vi) in any other
form of legal consideration that may be acceptable to the Board. 
 (e) Transferability of Options. The Board may, in its sole
discretion, impose such limitations on the transferability of Options as the Board shall determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options shall apply: 

 (i) Restrictions on Transfer. An Option shall not be transferable except by will or by the laws of descent and distribution and
shall be exercisable during the lifetime of the Optionholder only by the Optionholder. 
 (ii) Domestic Relations Orders.
Notwithstanding the foregoing, an Option may be transferred pursuant to a domestic relations order; provided, however, that if an Option is an Incentive Stock Option, such Option shall be deemed to be a Nonstatutory Stock Option as a result
of such transfer. 
 (iii) Beneficiary Designation. Notwithstanding the foregoing, the Optionholder may, by delivering written notice
to the Company, in a form provided by or otherwise satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option. In the absence of such a designation,
the executor or administrator of the Optionholder’s estate shall be entitled to exercise the Option. 
 (f) Vesting of Options
Generally. The total number of shares of Common Stock subject to an Option may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option may be subject to such other terms and conditions on the time
or times when it may or may not be exercised (which may be based on performance or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. The provisions of this Section 6(f) are subject to any
Option provisions governing the minimum number of shares of Common Stock as to which an Option may be exercised.  

  
 9 

 (g) Minimum Vesting. Notwithstanding the foregoing Section 6(f), to the extent that
the following restrictions on vesting are required by Section 260.140.41(f) of Title 10 of the California Code of Regulations at the time of the grant of the Option, then:  

(i) Options granted to an Employee who is not an Officer, Director or Consultant shall provide for vesting of the total number of shares
of Common Stock at a rate of at least twenty percent (20%) per year over five (5) years from the date the Option was granted, subject to reasonable conditions such as continued employment; and 

(ii) Options granted to Officers, Directors or Consultants may be made fully exercisable, subject to reasonable conditions such as
continued employment, at any time or during any period established by the Company. 
 (h) Termination of Continuous Service. In the
event that an Optionholder’s Continuous Service terminates (other than upon the Optionholder’s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option
as of the date of termination of Continuous Service) but only within such period of time ending on the earlier of (i) the date three (3) months following the termination of the Optionholder’ s Continuous Service (or such longer or
shorter period specified in the Option Agreement, which period shall not be less than thirty (30) days), or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service,
the Optionholder does not exercise his or her Option within the time specified herein or in the Option Agreement (as applicable), the Option shall terminate.  

(i) Extension of Termination Date. An Optionholder’s Option Agreement may also provide that if the exercise of the Option following
the termination of the Optionholder’s Continuous Service (other than upon the Optionholder’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration
requirements under the Securities Act, then the Option shall terminate on the earlier of (i) the expiration of a period of three (3) months after the termination of the Optionholder’s Continuous Service during which the exercise of
the Option would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option as set forth in the Option Agreement.  

(j) Disability of Optionholder. In the event that an Optionholder’s Continuous Service terminates as a result of the
Optionholder’s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination of Continuous Service), but only within such period of time
ending on the earlier of (i) the date twelve (12) months following such termination of Continuous Service (or such longer or shorter period specified in the Option Agreement, which period shall not be less than six (6) months), or
(ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Optionholder does not exercise his or her Option within the time specified herein or in the Option Agreement
(as applicable), the Option shall terminate.  
 (k) Death of Optionholder. In the event that (i) an Optionholder’s
Continuous Service terminates as a result of the Optionholder’s death or (ii) the Optionholder dies within the period (if any) specified in the Option Agreement after the termination of the Optionholder’s Continuous Service for a
reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder’s estate, by a person who acquired the right to exercise the Option by
bequest or inheritance or by a person designated to exercise the option upon the Optionholder’ s death pursuant to Section 6(e)(iii), but only within the period ending on the earlier of (i) the date eighteen (18) months following
the date of death (or such longer or shorter period specified in the Option Agreement, which period shall not be less than six (6) months), or (ii) the  

  
 10 

 
expiration of the term of such Option as set forth in the Option Agreement. If, after the Optionholder’s death, the Option is not exercised within the time specified herein or in the Option
Agreement (as applicable), the Option shall terminate. 
 (l) Early Exercise. The Option may include a provision whereby the
Optionholder may elect at any time before the Optionholder’ s Continuous Service terminates to exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full vesting of the Option. Subject to the
“Repurchase Limitation” in Section 9(i), any unvested shares of Common Stock so purchased may be subject to a repurchase option in favor of the Company or to any other restriction the Board determines to be appropriate. Provided that
the “Repurchase Limitation” in Section 9(i) is not violated, the Company shall not be required to exercise its repurchase option until at least six (6) months (or such longer or shorter period of time necessary to avoid a charge
to earnings for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically provides in the Option Agreement.  

(m) Right of Repurchase. Subject to the “Repurchase Limitation” in Section 9(i), the Option may include a provision
whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Optionholder pursuant to the exercise of the Option. Provided that the “Repurchase Limitation” in Section 9(i) is not
violated, the Company shall not be required to exercise its repurchase option until at least six (6) months (or such longer or shorter period of time necessary to avoid classification of the Option as a liability for financial accounting
purposes) have elapsed following exercise of the Option unless otherwise specifically provided in the Option Agreement. 
 (n)
Right of First Refusal. The Option may include a provision whereby the Company may elect to exercise a right of first refusal following receipt of notice from the Optionholder of the intent to transfer all or any part of the shares of Common
Stock received upon the exercise of the Option. Except as expressly provided in this Section 6(n) or in the Stock Award Agreement for the Option, such right of first refusal shall otherwise comply with any applicable provisions of the Bylaws of
the Company. The Company will not exercise its right of first refusal until at least six (6) months (or such longer or shorter period of time necessary to avoid classification of the Option as a liability for financial accounting purposes) have
elapsed following exercise of the Option unless otherwise specifically provided in the Option Agreement. 
  

	7.	PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS.  

 (a) Restricted Stock
Awards. Each Restricted Stock Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. At the Board’s election, shares of Common Stock may be (i) held in book entry form
subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which certificate shall be held in such form and manner as determined by the Board. The terms
and conditions of the Restricted Stock Award agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award agreements need not be identical; provided, however, that each Restricted
Stock Award agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:  

(i) Purchase Price. At the time of the grant of a Restricted Stock Award, the Board will determine the price to be paid by the
Participant for each share subject to the Restricted Stock Award. Subject to the provisions of Section 5(b) regarding Ten Percent Stockholders and to the extent required by applicable law, the price to be paid by the Participant for each share
subject to the Restricted Stock Award shall not be less than eighty-five percent (85%) of the Common Stock’s Fair Market Value on the date such award is made or at the time the purchase is consummated. Notwithstanding the foregoing, a

  
 11 

 
Restricted Stock Award may be awarded as a stock bonus (i.e., with no cash purchase price to be paid) to the extent permissible under applicable law. 

(ii) Consideration. At the time of the grant of a Restricted Stock Award, the Board will determine the consideration permissible for the
payment of the purchase price of the Restricted Stock Award. The purchase price of Common Stock acquired pursuant to the Restricted Stock Award shall be paid either: (i) in cash or by check at the time of purchase; (ii) at the discretion
of the Board, according to a deferred payment or other similar arrangement with the Participant; (iii) by past or future services rendered to the Company or an Affiliate; or (iv) in any other form of legal consideration that may be
acceptable to the Board in its sole discretion and permissible under applicable law. 
 (iii) Vesting. Subject to the “Repurchase
Limitation” in Section 9(i), shares of Common Stock acquired under a Restricted Stock Award may be subject to a share repurchase right or option in favor of the Company in accordance with a vesting schedule to be determined by the Board.

 (iv) Termination of Participant’s Continuous Service. Subject to the “Repurchase Limitation” in Section 9(i),
in the event that a Participant’s Continuous Service terminates, the Company shall have the right, but not the obligation, to repurchase or otherwise reacquire, any or all of the shares of Common Stock held by the Participant that have not
vested as of the date of termination under the terms of the Restricted Stock Award agreement. At the Board’s election, the price paid for all shares of Common Stock so repurchased or reacquired by the Company may be at the lesser of
(i) the Fair Market Value on the relevant date, or (ii) the Participant’s original cost for such shares. Provided that the “Repurchase Limitation” in Section 9(i) is not violated, the Company shall not be required to
exercise its repurchase or reacquisition option until at least six (6) months (or such longer or shorter period of time necessary to avoid classification of the Restricted Stock Award as a liability for financial accounting purposes) have
elapsed following the Participant’s purchase of the shares acquired pursuant to the Restricted Stock Award unless otherwise determined by the Board or provided in the Restricted Stock Award Agreement. 

(v) Transferability. Rights to purchase or acquire shares of Common Stock under the Restricted Stock Award agreement shall not be
transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Participant only by the Participant. 

(b) Stock Appreciation Rights. Each Stock Appreciation Right Agreement shall be in such form and shall contain such terms and conditions
as the Board shall deem appropriate. The terms and conditions of Stock Appreciation Right Agreements may change from time to time, and the terms and conditions of separate Stock Appreciation Right Agreements need not be identical;
provided, however, that but each Stock Appreciation Right Agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

 (i) Term. Subject to the provisions of Section 5(b) regarding Ten Percent Stockholders, no Stock Appreciation Right shall
be exercisable after the expiration of ten (10) years from the date of grant, or such shorter period specified in the Stock Appreciation Right Agreement. 

(ii) Strike Price. Each Stock Appreciation Right will be denominated in shares of Common Stock equivalents. Subject to the provisions of
Section 5(b) regarding Ten Percent Stockholders, the strike price of each Stock Appreciation Right granted as a stand-alone or tandem Stock Award shall not be less than one hundred percent (100%) of the Fair Market Value of the Common
Stock equivalents subject to the Stock Appreciation Right on the date of grant. 

  
 12 

 (iii) Calculation of Appreciation. The appreciation distribution payable on the exercise
of a Stock Appreciation Right will be not greater than an amount equal to the excess of (i) the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation Right) of a number of shares of Common Stock equal to the number
of share of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right and with respect to which the Participant is exercising the Stock Appreciation Right on such date, over (ii) an amount (the strike
price) that will be determined by the Board on the date of grant. 
 (iv) Vesting. At the time of the grant of a Stock Appreciation
Right, the Board may impose such restrictions or conditions to the vesting of such Stock Appreciation Right as it deems appropriate; provided, however, that a Stock Appreciation Right that could be settled in shares of Common Stock shall be
subject to the provision of Section 9(i). 
 (v) Exercise. To exercise any outstanding Stock Appreciation Right, the Participant must
provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right. 

(vi) Payment. The appreciation distribution in respect to a Stock Appreciation Right may be paid in Common Stock, in cash, in any
combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right. 

(vii) Termination of Continuous Service. In the event that a Participant’s Continuous Service terminates, the Participant may
exercise his or her Stock Appreciation Right (to the extent that the Participant was entitled to exercise such Stock Appreciation Right as of the date of termination) but only within such period of time ending on the earlier of (i) the date
three (3) months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the Stock Appreciation Right Agreement), or (ii) the expiration of the term of the Stock Appreciation
Right as set forth in the Stock Appreciation Right Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Stock Appreciation Right within the time specified herein or in the Stock Appreciation Right
Agreement (as applicable), the Stock Appreciation Right shall terminate. 
  

	8.	COVENANTS OF THE COMPANY.  

 (a) Availability of Shares. During the terms
of the Stock Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Stock Awards. 

(b) Securities Law Compliance. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the
Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking shall not require the Company to register
under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority
that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and
until such authority is obtained.  
  

	9.	MISCELLANEOUS.  

 (a) Use of Proceeds. Proceeds from the sale of Common
Stock pursuant to Stock Awards shall constitute general funds of the Company.  

  
 13 

 (b) Acceleration of Exercisability and Vesting. The Board shall have the power to
accelerate the time at which a Stock Award may first be exercised or the time during which a Stock Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Stock Award stating the time at which it may
first be exercised or the time during which it will vest.  
 (c) Stockholder Rights. No Participant shall be deemed to be the
holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms. 

 (d) No Employment or other Service Rights. Nothing in the Plan, any Stock Award Agreement, or any other instrument executed
thereunder or any Stock Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the
Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an
Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. 

 (e) Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined at the time of
grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds one hundred thousand dollars ($100,000),
the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). 

(f) Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock
Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is
knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written
assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock.
The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (i) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then
currently effective registration statement under the Securities Act, or (ii) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then
applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws,
including, but not limited to, legends restricting the transfer of the Common Stock.  
 (g) Withholding Obligations. To the
extent provided by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means (in addition to the
Company’s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares
of Common Stock issued or otherwise issuable to the Participant in connection with the Stock  

  
 14 

 
Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lower amount as may be
necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); or (iii) by such other method as may be set forth in the Stock Award Agreement.  

(h) Information Obligation. To the extent required by Section 260.140.46 of Title 10 of the California Code of Regulations, the
Company shall deliver financial statements to Participants at least annually. This Section 9(h) shall not apply to key Employees whose duties in connection with the Company assure them access to equivalent information.  

(i) Repurchase Limitation. The terms of any repurchase option shall be specified in the Stock Award, and the repurchase price may be
either the Fair Market Value of the shares of Common Stock on the date of termination of Continuous Service or the lower of (i) the Fair Market Value of the shares of Common Stock on the date of repurchase, or (ii) their original purchase
price. To the extent required by Section 260.140.41 and Section 260.140.42 of Title 10 of the California Code of Regulations at the time a Stock Award is made, any repurchase option contained in a Stock Award granted to a person who is not
an Officer, Director or Consultant shall be upon the terms described below:  
 (i) Fair Market Value. If the repurchase option
gives the Company the right to repurchase the shares of Common Stock upon termination of Continuous Service at not less than the Fair Market Value of the shares of Common Stock to be purchased on the date of termination of Continuous Service, then
(i) the right to repurchase shall be exercised for cash or cancellation of purchase money indebtedness for the shares of Common Stock within ninety (90) days of termination of Continuous Service (or in the case of shares of Common Stock
issued upon exercise of Stock Awards after such date of termination, within ninety (90) days after the date of the exercise) or such longer period as may be agreed to by the Company and the Participant, and (ii) the right terminates when
the shares of Common Stock become publicly traded. 
 (ii) Original Purchase Price. If the repurchase option gives the Company the
right to repurchase the shares of Common Stock upon termination of Continuous Service at the lower of (i) the Fair Market Value of the shares of Common Stock on the date of repurchase or (ii) their original purchase price, then
(x) the right to repurchase at the original purchase price shall lapse at the rate of at least twenty percent (20%) of the shares of Common Stock per year over five (5) years from the date the Stock Award is granted (without respect
to the date the Stock Award was exercised or became exercisable) and (y) the right to repurchase shall be exercised for cash or cancellation of purchase money indebtedness for the shares of Common Stock within ninety (90) days of
termination of Continuous Service (or in the case of shares of Common Stock issued upon exercise of Options after such date of termination, within ninety (90) days after the date of the exercise) or such longer period as may be agreed to by the
Company and the Participant. 
 (j) Electronic Delivery. Any reference herein to a “written” agreement or document shall
include any agreement or document delivered electronically or posted on the Company’s intranet. 
  

	10.	ADJUSTMENTS UPON CHANGES IN COMMON STOCK; CORPORATE TRANSACTIONS.  

 (a)
Capitalization Adjustments. If any change is made in, or other events occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award without the receipt of consideration .by the Company (through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving
the receipt of  

  
 15 

 
consideration by the Company (each a “Capitalization Adjustment”), the Board shall appropriately adjust: (i) the class(es) and maximum number of securities
subject to the Plan pursuant to Sections 4(a) and 4(b), and (ii) the class(es) and number of securities and price per share of Common Stock subject to each outstanding Stock Award. The Board shall make such adjustments, and its determination
shall be final, binding and conclusive. (Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a transaction “without receipt of consideration” by the Company.) 

 (b) Dissolution or Liquidation. In the event of a dissolution or liquidation of the Company, all outstanding Stock Awards
(other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to the Company’s right of repurchase) shall terminate immediately prior to the completion of such dissolution or liquidation, and the shares of
Common Stock subject to the Company’s repurchase option may be repurchased by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may,
in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or
liquidation is completed but contingent on its completion.  
 (c) Corporate Transaction. The following provisions shall apply
to Stock Awards in the event of a Corporate Transaction unless otherwise provided in a written agreement between the Company or any Affiliate and the holder of the Stock Award:  

(i) Stock Awards May Be Assumed. In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the
surviving or acquiring corporation’s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to,
awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be
assigned by the Company to the successor of the Company (or the successor’s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation may choose to assume or continue only a portion
of a Stock Award or substitute a similar stock award for only a portion of a Stock Award. The terms of any assumption, continuation or substitution shall be set by the Board in accordance with the provisions of Section 3. 

(ii) Stock Awards Held by Current Participants. In the event of a Corporate Transaction in which the surviving corporation or acquiring
corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or
substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the “Current Participants”), the vesting of such Stock Awards (and, if
applicable, the time at which such Stock Awards may be exercised) shall (contingent upon the effectiveness of the Corporate Transaction) be accelerated in full to a date prior to the effective time of such Corporate Transaction as the Board shall
determine (or, if the Board shall not determine such a date, to the date that is five (5) days prior to the effective time of the Corporate Transaction), and such Stock Awards shall terminate if not exercised (if applicable) at or prior to the
effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall lapse (contingent upon the effectiveness of the Corporate Transaction). 

  
 16 

 (iii) Stock Awards Held by Former Participants. In the event of a Corporate Transaction in
which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that
have not been assumed, continued or substituted and that are held by persons other than Current Participants, the vesting of such Stock Awards (and, if applicable, the time at which such Stock Award may be exercised) shall not be accelerated and
such Stock Awards (other than a Stock Award consisting of vested and outstanding shares of Common Stock not subject to the Company’s right of repurchase) shall terminate if not exercised (if applicable) prior to the effective time of the
Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall not terminate and may continue to be exercised notwithstanding the Corporate Transaction. 

(iv) Payment for Stock Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event a Stock Award will terminate if not
exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but will receive a payment, in such form as may be determined by
the Board, equal in value to the excess, if any, of (i) the value of the property the holder of the Stock Award would have received upon the exercise of the Stock Award, over (ii) any exercise price payable by such holder in connection
with such exercise. 
 (d) Change in Control. A Stock Award may be subject to additional acceleration of vesting and exercisability
upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant. A Stock Award may vest as to all or
any portion of the shares subject to the Stock Award (i) immediately upon the occurrence of a Change in Control, whether or not such Stock Award is assumed, continued, or substituted by a surviving or acquiring entity in the Change in Control,
or (ii) in the event a Participant’s Continuous Service is terminated, actually or constructively, within a designated period following the occurrence of a Change in Control. In the absence of such provisions, no such acceleration shall
occur.  
  

	11.	AMENDMENT OF THE PLAN AND STOCK AWARDS.  

 (a) Amendment of Plan. Subject
to the limitations, if any, of applicable law, the Board at any time, and from time to time, may amend the Plan. However, except as provided in Section 10(a) relating to Capitalization Adjustments, no amendment shall be effective unless
approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy applicable law.  
 (b)
Stockholder Approval. The Board, in its sole discretion, may submit any other amendment to the Plan for stockholder approval.  

(c) Contemplated Amendments. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or
advisable to provide eligible Employees with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options and/or to bring the Plan and/or Incentive
Stock Options granted under it into compliance therewith.  
 (d) No Impairment of Rights. Rights under any Stock Award granted
before amendment of the Plan shall not be impaired by any amendment of the Plan unless (i) the Company requests the consent of the affected Participant, and (ii) such Participant consents in writing.  

  
 17 

 (e) Amendment of Stock Awards. The Board, at any time and from time to time, may amend the
terms of any one or more Stock Awards; provided, however, that the rights under any Stock Award shall not be impaired by any such amendment unless (i) the Company requests the consent of the affected Participant, and
(ii) such Participant consents in writing.  
  

	12.	TERMINATION OR SUSPENSION OF THE PLAN.  

 (a) Plan Term. The Board may
suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate on the day before the tenth (10th) anniversary of the earlier of the date the Plan, as amended and restated, is (i) adopted by the Board, or
(ii) approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.  

(b) No Impairment of Rights. Suspension or termination of the Plan shall not impair rights and obligations under any Stock Award granted
while the Plan is in effect except with the written consent of the affected Participant.  
  

	13.	EFFECTIVE DATE OF PLAN.  

 Prior to expiration of its original ten (10) year
term, the Plan was amended and restated by the Board to provide that it shall continue in effect for an additional ten (10) year term. The Plan, as so amended and restated, shall become effective on the date approved by the Board, but no Stock
Award shall be exercised (or, in the case of a Restricted Stock Award, shall be granted) unless and until the Plan has been approved by the stockholders of the Company, which approval shall be within twelve (12) months before or after the date
the Plan is adopted by the Board. 
  

	14.	CHOICE OF LAW.  

 The law of the State of Delaware shall govern all questions
concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules. 

  
 18 

 ANAPTYSBIO, INC. 

2006 EQUITY INCENTIVE PLAN 

STOCK OPTION AGREEMENT 

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) 

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, AnaptysBio,
Inc. (the “Company”) has granted you an option under its 2006 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at
the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.  

The details of your option are as follows: 

1. VESTING. Subject To The Limitations Contained Herein, Your Option Will Vest As Provided In Your Grant
Notice, Provided That Vesting Will Cease Upon The Termination Of Your Continuous Service. 
 2. NUMBER OF
SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted
from time to time for Capitalization Adjustments. 
 3. EXERCISE RESTRICTION FOR
NON-EXEMPT EMPLOYEES. In the event that you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended ( i.e., a “Non-Exempt
Employee”), you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant specified in your Grant Notice, notwithstanding any other provision of your option. 

4. EXERCISE PRIOR TO VESTING (“EARLY
EXERCISE”). If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates that “Early Exercise” of your option is permitted) and subject to the provisions of your option, you may
elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the nonvested portion of your option; provided, however,
that: 
 (a) a partial exercise of your option shall be deemed to cover first vested shares of Common Stock and then the earliest
vesting installment of unvested shares of Common Stock; 
 (b) any shares of Common Stock so purchased from installments that have not
vested as of the date of exercise shall be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

(c) you shall enter into the Company’s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will result in
the same vesting as if no early exercise had occurred; and 
 (d) if your option is an Incentive Stock Option, then, to the extent
that the aggregate Fair Market Value (determined at the time of grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by you during any calendar year
(under all plans of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock
Options. 

  
 1 

 5. METHOD OF PAYMENT. Payment
of the exercise price is due in full upon exercise all or any part of your option. You may elect to make payment of the exercise price in cash or by check or in any other manner, which may include one or more of the following: 

(a) Provided that at the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street Journal,
pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to
pay the aggregate exercise price to the Company from the sales proceeds. 
 (b) Provided that at the time of exercise the Common Stock
is publicly traded and quoted regularly in The Wall Street Journal, by delivery of already-owned shares of Common Stock either that you have held for the period required to avoid a charge to the Company’s reported earnings (generally six
(6) months) or that you did not acquire, directly or indirectly from the Company, that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise.
“Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, shall include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the
Company. Notwithstanding the foregoing, you may not exercise your option by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the
Company’s stock. 
 6. WHOLE SHARES. You may exercise your option only for whole
shares of Common Stock. 
 7. SECURITIES LAW COMPLIANCE. Notwithstanding
anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the
Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with other applicable laws and regulations governing your option, and you
may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations. 

8. TERM. You may not exercise your option before the commencement or after the expiration of its term.
The term of your option commences on the Date of Grant and expires upon the earliest of the following: 
 (a) three (3) months
after the termination of your Continuous Service for any reason other than your Disability or death, provided that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in
Section 7, your option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; 

(b) twelve (12) months after the termination of your Continuous Service due to your Disability; 

(c) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after
your Continuous Service terminates; 
 (d) the Expiration Date indicated in your Grant Notice; or 

(e) the day before the tenth (10th) anniversary of the Date of Grant. 

  
 2 

 If your option is an Incentive Stock Option, note that to obtain the federal income tax
advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your option and ending on the day three (3) months before the date of your option’s exercise, you must be an
employee of the Company or an Affiliate, except in the event of your death or your Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option
will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three
(3) months after the date your employment with the Company or an Affiliate terminates. 
 9.
EXERCISE. 
 (a) You may exercise the vested portion of your option (and the unvested portion of
your option if your Grant Notice so permits) during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may
designate, during regular business hours, together with such additional documents as the Company may then require. 
 (b) By
exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising
by reason of (1) the exercise of your option, (2) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (3) the disposition of shares of Common Stock acquired upon
such exercise. 
 (c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the
Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option. grant or within one
(1) year after such shares of Common Stock are transferred upon exercise of your option. 
 (d) By exercising your option you
agree that you shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other
securities of the Company held by you, for a period of time specified by the managing underwriter(s) (not to exceed one hundred eighty (180) days (or such longer period, not to exceed 18 days after the expiration of the 180-day period, as the
underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711) following the effective date of a registration statement of the Company filed under the Securities Act (the “Lock Up Period”);
provided, however, that nothing contained in this section shall prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock Up Period. You further agree to execute and deliver such other agreements as may be
reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to your shares of Common Stock until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9(d) and shall have the right, power and authority to enforce the
provisions hereof as though they were a party hereto. 
 10. TRANSFERABILITY. Your option is not
transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may
designate a third party who, in the event of your death, shall thereafter be entitled to exercise your option. 

  
 3 

 11. CHANGE IN CONTROL. 

 (a) If a Change in Control occurs and within thirteen (13) months after the effective time of such Change in Control your
Continuous Service terminates due to an involuntary termination of your employment (not including death or Disability) without Cause (as defined below) or due to a voluntary termination by you with Good Reason (as defined below), then, as of the
date of termination of Continuous Service, the vesting and exercisability of your option shall be accelerated in full. 
 (b)
“Cause” means the occurrence of any one or more of the following: (i) your commission of any crime involving fraud, dishonesty or moral turpitude; (ii) your attempted commission of or participation in a fraud or act
of dishonesty against the Company that results in (or might have reasonably resulted in) material harm to the business of the Company; (iii) your intentional, material violation of any contract or agreement between you and the Company or any
statutory duty you owe to the Company; or (iv) your conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the
Company; provided, however, that the action or conduct described in clauses (iii) and (iv) above will constitute “Cause” only if such action or conduct continues after the Company has provided you with written notice
thereof and thirty (30) days to cure the same. 
 (c) “Good Reason” shall mean any of the following
actions taken without Cause by the Company or a successor corporation or entity without your consent: (i) the assignment to you of any duties or responsibilities that results in a material diminution in your function as in effect immediately
prior to the effective date of the Change in Control; provided, however, that a change in your title or reporting relationships shall not provide the basis for a voluntary termination with Good Reason; (ii) a reduction by the Company in
your annual base salary as in effect on the effective date of the Change in Control; provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your annual base salary that is pursuant to a salary
reduction program affecting substantially all of the employees of the Company and that does not adversely affect you to a greater extent than other similarly situated employees; or (iii) a relocation of your primary business office to a
location more than 50 miles from the location of your primary business office as of the effective date of the Change in Control, except for required travel by you on the Company’s business to an extent substantially consistent with your
business travel obligations prior to the effective date of the Change in Control. 
 (d) If any payment or benefit you would receive
pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be
subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”, then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the
Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and
local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the
Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order
unless you elect in writing a different order (provided, however, that such election shall be subject to Company approval if made on or after the effective date of the event that triggers the Payment): reduction of cash payments; cancellation
of accelerated vesting of Stock Awards; reduction of employee benefits. In the event that acceleration of vesting of Stock Award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant
of your Stock Awards (i.e., earliest granted Stock Award cancelled last) unless you elect in writing a different order for cancellation. 

  
 4 

 The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date
of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a
nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 

The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to you and
the Company within fifteen (15) calendar days after the date on which your right to a Payment is triggered (if requested at that time by you or the Company) or such other time as requested by you or the Company. If the accounting firm
determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish you and the Company with an opinion reasonably acceptable to you that no Excise Tax will be imposed
with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon you and the Company. 

12. RIGHT OF FIRST REFUSAL. Shares of Common Stock that you
acquire upon exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided, however, that if your option is an
Incentive Stock Option and the right of first refusal described in the Company’s bylaws in effect at the time the Company elects to exercise its right is more beneficial to you than the right of first refusal described in the Company’s
bylaws on the Date of Grant, then the right of first refusal described in the Company’s bylaws on the Date of Grant shall apply. The Company’s right of first refusal shall expire on the Listing Date. For purposes of this Agreement, Listing
Date shall mean the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on a national securities exchange or on the National Market System of the Nasdaq Stock Market (or any successor to that
entity). 
 13. RIGHT OF REPURCHASE. To the extent provided in the
Company’s bylaws in effect at such time the Company elects to exercise its right, the Company shall have the right to repurchase all or any part of the shares of Common Stock you acquire pursuant to the exercise of your option. 

14. OPTION NOT A SERVICE CONTRACT. Your
option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to
continue your employment. In addition, nothing in your option shall obligate the Company or an Affiliate, their respective stockholders, Boards of Directors, Officers or Employees to continue any relationship that you might have as a Director or
Consultant for the Company or an Affiliate. 
 15. WITHHOLDING OBLIGATIONS.  

(a) At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “cashless exercise” pursuant to a program developed under Regulation T as promulgated by
the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of
your option. 
 (b) Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any
applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of 

  
 5 

 
whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such
lower amount as may be necessary to avoid variable award accounting). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding
sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is
otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of
Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.

 (c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.
Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein unless such obligations are satisfied. 
 16. NOTICES. Any notices provided
for in your option or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage
prepaid, addressed to you at the last address you provided to the Company. 
 17. GOVERNING PLAN
DOCUMENT. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations,
which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the Plan, the provisions of the Plan shall control. 

  
 6 

 ANAPTYSBIO, INC. 

2006 EQUITY INCENTIVE PLAN 

OPTION GRANT NOTICE 

AnaptysBio, Inc. (the “Company”), pursuant to its 2006 Equity Incentive Plan (the “Plan”), hereby grants to
Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth herein and in the Option Agreement, the Plan, and the Notice of
Exercise, all of which are attached hereto and incorporated herein in their entirety. 
  

			
	Optionholder:	 	  

	Date of Grant: Vesting	 	  

	Vesting Commencement Date:	 	  

	Number of Shares Subject to Option:	 	  

	Exercise Price (Per Share):	 	  

	Total Exercise Price:	 	  

	Expiration Date:	 	  

  

					
	Type of Grant:	  	☐ Incentive Stock Option1	  	☐ Nonstatutory Stock Option
			
	Exercise Schedule:	  	☐ Same as Vesting Schedule	  	☐ Early Exercise Permitted
		
	Vesting Schedule:	  	1/4th of the shares vest and become exercisable one year after the Vesting Commencement Date; the
balance of the shares vest and become exercisable in a series of thirty-six (36)
successive equal monthly
installments measured from the first anniversary of the Vesting Commencement Date; provided, however,
that the vesting and exercisability of this option shall be subject to the special acceleration provisions
set
forth in the Stock Option Agreement attached hereto.
		
	Payment:	  	By one or a combination of the following items (described in the Option Agreement):
		
		  	☒ By cash or check ̈
		
		  	☐ Pursuant to a Regulation T Program if the Shares are publicly traded
		
		  	☐ By delivery of already-owned shares if the Shares are publicly traded
		
		  	☐ By net exercise2

  
  

 

	1 	If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over
$100,000 is a Nonstatutory Stock Option. 

	2 	An Incentive Stock Option may not be exercised by a net exercise agreement. 

  
 1 

 Additional Terms/Acknowledgements: The undersigned Optionholder acknowledges receipt of, and understands
and agrees to, this Option Grant Notice, the Option Agreement, and the Plan. Optionholder further acknowledges that as of the Date of Grant, this Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between
Optionholder and the Company regarding the acquisition of stock in the Company and supersede all prior oral and written agreements on that subject with the exception of (i) options previously granted and delivered to Optionholder under the
Plan, and (ii) the following agreements only: 
  

			
	OTHER AGREEMENTS:  	 	  

		 	  

  
  

									
	ANAPTYS BIOSCIENCES, INC.	  		  	OPTIONHOLDER:
				
	By:	 	  
	  		  	  

		 	Signature	  		  		 	Signature
					
	Title:	 	  
	  		  	Date:	 	  

					
	Date:	 	  
	  		  		 	

 ATTACHMENTS: Option Agreement, 2006 Equity Incentive Plan, and Notice of Exercise 

  
 2 

 ATTACHMENT III 

NOTICE OF EXERCISE 
  

					
	AnaptysBio, Inc.	 		  	Date of Exercise:                              

			
	  
	 		  	
			
	  
	 		  	

 Ladies and Gentlemen: 
 This
constitutes notice under my stock option that I elect to purchase the number of shares for the price set forth below. 
  

									
	 Type of option (check one):
	  	 	Incentive  ☐	  	  	 	Nonstatutory  ☐	  
	 Stock option dated:
	  	 	__________	  	  			
	 Number of shares as to which option is exercised:
	  	 	__________	  	  			
	 Certificates to be issued in name of:
	  	 	__________	  	  			
	 Total exercise price:
	  	 	$_________	  	  			
	 Cash payment delivered herewith:
	  	 	$_________	  	  			
	 Value of             shares of
AnaptysBio, Inc. common stock delivered herewith:3
	  	 	$_________	  	  			

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the AnaptysBio, Inc. 2006 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this
exercise relates to an incentive stock option, to notify you in writing within fifteen (15) days after the date of any disposition of any of the shares of Common Stock issued upon exercise of this option that occurs within two (2) years
after the date of grant of this option or within one (1) year after such shares of Common Stock are issued upon exercise of this option. 
  

 

	3 	Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance with the terms of the option being exercised, must have been owned for the minimum period required in the
option, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate. 

  
 1 

 I hereby make the following certifications and representations with respect to the
number of shares of Common Stock of the Company listed above (the “Shares”), which are being acquired by me for my own account upon exercise of the Option as set forth above:  

I acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), and are deemed to constitute “restricted securities” under Rule 701 and “control securities” under Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present
intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws.  

I further acknowledge that I will not be able to resell the Shares for at least ninety (90) days after the stock of the Company becomes
publicly traded (i.e., subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 

I further acknowledge that all certificates representing any of the Shares subject to the provisions of the Option shall have endorsed thereon
appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Certificate of Incorporation, Bylaws and/or applicable securities laws. 

I further agree that I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into
any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other securities of the Company held by me, for a period of time specified by the managing underwriter(s) (not to exceed one hundred eighty
(180) days (or such longer period, not to exceed 18 days after the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711) following the effective date of a
registration statement of the Company filed under the Securities Act (the “Lock Up Period”); provided, however, that nothing contained in this paragraph shall prevent the exercise of a repurchase option,
if any, in favor of the Company during the Lock Up Period. I further agree to execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are
necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to my shares of Common Stock until the end of such period. 

 

	
	Very truly yours,
	
	  

  
 1 

 ANAPTYSBIO, INC. 

RESTRICTED STOCK BONUS GRANT NOTICE 

(2006 EQUITY INCENTIVE PLAN) 
 AnaptysBio,
Inc. (the “Company”), pursuant to its 2006 Equity Incentive Plan (the “Plan”), hereby awards to Participant as compensation the number of shares of the Company’s Common Stock set forth below (“Award”). This Award
is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Bonus Agreement, the Plan, the form of Assignment Separate from Certificate and the form of Joint Escrow Instructions, all of which are attached hereto and
incorporated herein in their entirety. 
 Participant: 
 Date
of Grant: 
 Vesting Commencement Date: 
 Number of Shares
Subject to Award: 
 Consideration: 
 Vesting Schedule:
 
 Additional Terms/Acknowledgements: The undersigned Participant acknowledges receipt of, and understands and agrees to, this Restricted
Stock Bonus Grant Notice, the Restricted Stock Bonus Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Restricted Stock Bonus Grant Notice, the Restricted Stock Bonus Agreement and the Plan set forth the
entire understanding between Participant and the Company regarding the acquisition of stock in the Company and supersede all prior oral and written agreements on that subject with the exception of (i) Awards previously granted and delivered to
Participant under the Plan, and (ii) the following agreements only: 
  

			
	OTHER AGREEMENTS:	  	 
		
		  	 

  

									
	ANAPTYSBIO, INC.	 		 	PARTICIPANT:
				
	By:	 	  
	 		 	  

		 	Signature	 		 		 	Signature
					
	Title:	 	  
	 		 	Date:	 	  

					
	Date:	 	  
	 		 		 	

 ATTACHMENTS: 

  
 1 

 ATTACHMENT I 

RESTRICTED STOCK BONUS AGREEMENT 

  
 1 

 ANAPTYSBIO, INC. 

2006 EQUITY INCENTIVE PLAN 

RESTRICTED STOCK BONUS AGREEMENT 

Pursuant to the Restricted Stock Bonus Grant Notice (“Grant Notice”) and this Restricted Stock Bonus
Agreement (collectively, the “Award”) and in consideration of your services, AnaptysBio, Inc. (the “Company”) has awarded you a Restricted Stock Award under its 2006 Equity Incentive Plan (the
“Plan”) for the number of shares of the Company’s Common Stock subject to the Award as indicated in the Grant Notice. Defined terms not explicitly defined in this Restricted Stock Bonus Agreement but defined in the Plan
shall have the same definitions as in the Plan. 
 The details of your Award are as follows: 

1. VESTING. Subject to the limitations contained herein, your Award will vest as provided in the Grant Notice, provided that vesting
will cease upon the termination of your Continuous Service. 
 2. NUMBER OF SHARES. The number of shares subject to your Award
may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan.  
 3. SECURITIES LAW COMPLIANCE.
You may not be issued any shares under your Award unless the shares are either (i) then registered under the Securities Act or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the
Securities Act. Your Award must also comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and
regulations.  
 4. MARKET STAND-OFF AGREEMENT. By acquiring shares of Common Stock under your Award, you shall not sell,
dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other securities of the Company held by you,
for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as necessary to permit compliance with NASD Rule 2711 and similar or
successor regulatory rules and regulations (the “Lock-Up Period”); provided, however, that nothing contained in this Section 4 shall prevent the exercise of a repurchase option, if any, in favor of the
Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further
effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. The underwriters of the Company’s stock are intended third
party beneficiaries of this Section 4 and shall have the right, power and authority to enforce the provision hereof as though they were a party hereto.  

5. RIGHT OF FIRST REFUSAL. Shares that are received under your Award are subject to any right of first refusal that may be described in
the Company’s bylaws in effect at such time the Company elects to exercise its right.  

  
 1 

 6. RIGHT OF REPURCHASE.  

(a) To the extent provided in the Company’s bylaws, as amended from time to time, the Company shall have the right to repurchase
all or any part of the shares received pursuant to your Award. 
 (b) The Company shall have a right to reacquire (a
“Reacquisition Right”) the shares you received pursuant to your Award that have not as yet vested in accordance with the Vesting Schedule on the Grant Notice (“Unvested Shares”) on the following terms
and conditions: 
 (i) The Company shall simultaneously with termination of your Continuous Service automatically reacquire for no
consideration all of the Unvested Shares, unless the Company agrees to waive its Reacquisition Right as to some or all of the Unvested Shares. Any such waiver shall be exercised by the Company by written notice to you or your representative (with a
copy to the Escrow Holder as defined below) within ninety (90) days after the termination of your Continuous Service, and the Escrow Holder may then release to you the number of Unvested Shares not being reacquired by the Company. If the
Company does not waive its Reacquisition Right as to all of the Unvested Shares, then upon such termination of your Continuous Service, the Escrow Holder shall transfer to the Company the number of shares the Company is reacquiring. 

(ii) The Company shall not exercise its Reacquisition Right until at least six (6) months (or such longer or shorter period of
time necessary to avoid classification of the Award as a liability for financial accounting purposes) have elapsed following delivery of shares of Common Stock subject to the Award, unless otherwise specifically provided by the Board. If the Company
does exercise its Reacquisition Right as to any of the shares subject to your Award, then upon such termination of your Continuous Service, the Escrow Holder shall transfer to the Company the number of shares the Company is repurchasing. 

(iii) The shares issued under your Award shall be held in escrow pursuant to the terms of the Joint Escrow Instructions attached to
the Grant Notice as Attachment IV. You agree to execute two (2) Assignment Separate From Certificate forms (with date and number of shares blank) substantially in the form attached to the Grant Notice as Attachment III and deliver the same,
along with the certificate or certificates evidencing the shares, for use by the escrow agent pursuant to the terms of the Joint Escrow Instructions. 

(iv) Subject to the provisions of your Award, you shall, during the term of your Award, exercise all rights and privileges of a
shareholder of the Company with respect to the shares deposited in escrow. You shall be deemed to be the holder of the shares for purposes of receiving any dividends which may be paid with respect to such shares and for purposes of exercising any
voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company’s Reacquisition Right. 

(v) If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the
outstanding stock of the corporation the stock of which is subject to the provisions of your Award, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares acquired
under your Award shall be immediately subject to the Reacquisition Right with the same force and effect as the shares subject to this Reacquisition Right immediately before such event. 

(vi) In the event of a Corporate Transaction as defined in the Plan, the Reacquisition Right may be assigned by the Company to the
successor of the Company (or such successor’s parent company), if any, in connection with such transaction. To the extent the Reacquisition  

  
 2 

 
Right remains in effect following such transaction, it shall apply to the new capital stock, cash or other property received in exchange for the Common Stock in consummation of the
transaction, but only to the extent the Common Stock was at the time covered by such right. If any Reacquisition Right is not assumed or substituted in connection with such transaction and your continuous service has not terminated prior to the
effective time of the Corporate Transaction, the Reacquisition Right shall lapse prior to the effective time of the Corporate Transaction. If your continuous service has terminated prior to the effective time of the Corporate Transaction and the
surviving or acquiring corporation (or its parent company) does not assume or continue your outstanding Award, the Reacquisition Right held by the Company with respect to such Award may continue to be exercised notwithstanding the Corporate
Transaction. 
 (vii) In addition to any other limitation on transfer created by applicable securities laws, you shall not
sell, assign, hypothecate, donate, encumber, or otherwise dispose of any interest in the Common Stock while such shares of Common Stock are subject to the Reacquisition Right or continue to be held in the Joint Escrow; provided, however, that an
interest in such shares may be transferred pursuant to a qualified domestic relations order as defined in the Code or Title I of the Employee Retirement Income Security Act. After any Common Stock has been released from the Joint Escrow, you shall
not sell, assign, hypothecate, donate, encumber, or otherwise dispose of any interest in the Common Stock except in compliance with the provisions herein and applicable securities laws.  

7. RESTRICTIVE LEGENDS. The shares issued under your Award shall be endorsed with appropriate legends determined by the Company. 

 8. AWARD NOT A SERVICE CONTRACT. Your Award is not an employment or service contract, and nothing in your Award shall be
deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or on the part of the Company or an Affiliate to continue your employment. In addition, nothing in your Award shall obligate
the Company or an Affiliate, their respective shareholders, boards of directors, Officers or Employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.  

9. WITHHOLDING OBLIGATIONS. 

(a) At the time your Award is made, or at any time thereafter as requested by the Company, you hereby authorize withholding from
payroll and any other amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in
connection with your Award (the “Withholding Taxes”). The Company may, in its sole discretion; satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a
combination of such means: (i) withholding from any amounts otherwise payable to you by the Company or (ii) causing you to tender a cash payment; (iii) withholding shares of Common Stock from the shares of Common Stock issued or
otherwise issuable to you in connection with the Award. with a Fair Market Value equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld shall not exceed the amount necessary to
satisfy the Company’s required tax withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; or
(v) withholding cash from an Award settled in cash. 
 (b) Unless the tax withholding obligations of the Company and/or any
Affiliate are satisfied, the Company shall have no obligation to issue a certificate for such shares or release such shares from any escrow provided for herein.  

  
 3 

 10. TAX CONSEQUENCES. The acquisition and vesting of the shares may have adverse tax
consequences to you that may avoided or mitigated by filing an election under Section 83(b) of the Code. Such election must be filed within thirty (30) days after the date of your Award. YOU ACKNOWLEDGE THAT IT IS YOUR OWN RESPONSIBILITY,
AND NOT THE COMPANY’S, TO FILE A TIMELY ELECTION UNDER CODE SECTION 83(B), EVEN IF YOU REQUEST THE COMPANY TO MAKE THE FILING ON YOUR BEHALF. 

11. NOTICES. Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon
receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.  

12. MISCELLANEOUS,  

(a) The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities, and all
covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company’s successors and assigns. Your rights and obligations under your Award may only be assigned with the prior written consent of the Board in its
sole discretion.  
 (b) You agree upon request to execute any further documents or instruments necessary or desirable in the
sole determination of the Company to carry out the purposes or intent of your Award. 
 (c) You acknowledge and agree that you
have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award.  

13. GOVERNING PLAN DOCUMENT. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of
your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your Award and those of
the Plan, the provisions of the Plan shall control.  
 14. APPLICATION OF SECTION 409A. This Award is intended to be exempt
from the application of Section 409A of the Code (“Section 409A”) pursuant to Treasury Regulation 1.409A-l(b)(6). Notwithstanding the foregoing, if it is determined that the Award fails to satisfy the
requirements of Treasury Regulation l.409A-l(b)(6) or the short-term deferral rule and is otherwise deferred compensation subject to Section 409A, and if you are a “Specified Employee” (within the meaning set forth
Section 409A(a)(2)(B)(i) of the Code) as of the date of your separation from service (within the meaning of Treasury Regulation Section 1.409A-l(h)), then the vesting and/or issuance of any shares that would otherwise be made upon the date
of your separation from service or within the first six (6) months thereafter will not be made on the originally scheduled date(s) and will instead occur in a lump sum on the date that is six (6) months and one day after the date of the
separation from service, with the balance of the shares becoming vested or issued thereafter in accordance with the original vesting and issuance schedule set forth above, but if and only if such delay is necessary to avoid the imposition of
taxation on you in respect of the shares under Section 409A of the Code. Each installment of shares that vests is intended to constitute a “separate payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2). 

  
 4 

 ATTACHMENT II 

2006 EQUITY INCENTIVE PLAN 

  
 1 

 ATTACHMENT III 

FORM OF ASSIGNMENT SEPARATE FROM CERTIFICATE 

  
 1 

 ASSIGNMENT SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Bonus Grant Notice and Restricted Stock Bonus Agreement (the
“Award”),              hereby sells, assigns and transfers unto AnaptysBio, Inc., a Delaware corporation
(“Assignee”),              (            ) shares of the common stock of the Assignee,
standing in the undersigned’s name on the books of said corporation represented by Certificate No. herewith and do hereby irrevocably constitute and appoint as attorney-in-fact to transfer the said stock on the books of the within named Company
with full power of substitution in the premises. This Assignment may be used only in accordance with and subject to the terms and conditions of the Award, in connection with the repurchase of shares of Common Stock of the Corporation issued to the
undersigned pursuant to the Award, and only to the extent that such shares remain subject to the Corporation’s Reacquisition Right under the Award.  
  

									
	Dated:	 	 	 		 	
					
		 		 		 	Signature:	 	 
					
		 		 		 		 	                                ,
Recipient

 INSTRUCTION: Please do not fill in any blanks other than the signature line. The purpose of this Assignment is to
enable the Company to exercise its Reacquisition Right set forth in the Award without requiring additional signatures on your part.  

  
 1 

 ATTACHMENT IV 

FORM OF JOINT ESCROW INSTRUCTIONS 

JOINT ESCROW INSTRUCTIONS 
 [Date] 

Corporate Secretary 
 AnaptysBio, Inc. 

10421 Pacific Center Court, Suite 200 
 San Diego, CA 92121 

Dear Sir/Madam: 
 As Escrow Agent
for both AnaptysBio, Inc., a Delaware corporation (the “Company”), and the undersigned recipient of stock of the Company (“Recipient”), you are hereby authorized and directed to hold the documents
delivered to you pursuant to the terms of that certain Restricted Stock Bonus Grant Notice (the “Grant Notice”), dated              to which a copy of these Joint
Escrow Instructions is attached as Attachment IV, and pursuant to the terms of that certain Restricted Stock Bonus Agreement
                (“Agreement”), which is Attachment I to the Grant Notice, in accordance with the following instructions:  

1. In the event Recipient ceases to render services to the Company or an affiliate of the Company during the vesting period set forth
in the Grant Notice, the Company or its assignee will give to Recipient and you a written notice specifying that the shares of Common Stock shall be transferred to the Company. Recipient and the Company hereby irrevocably authorize and direct you to
close the transaction contemplated by such notice in accordance with the terms of said notice.  
 2. At the closing you are
directed (a) to date any stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver same, together with the certificate evidencing the shares of Common Stock to
be transferred, to the Company.  
 3. Recipient irrevocably authorizes the Company to deposit with you any certificates
evidencing shares of Common Stock to be held by you hereunder and any additions and substitutions to said shares as specified in the Grant Notice. Recipient does hereby irrevocably constitute and appoint you as Recipient’s attorney-in-fact and
agent for the term of this escrow to execute with respect to such securities and other property all documents of assignment and/or transfer and all stock certificates necessary or appropriate to make all securities negotiable and complete any
transaction here.in contemplated.  
 4. This escrow shall terminate upon vesting of the shares or upon the earlier return of
the shares to the Company pursuant to the Company’s Reacquisition Right or other forfeiture condition under the Plan.  

5. If at the time of termination of this escrow you should have in your possession any documents, securities, or other property
belonging to Recipient, you shall deliver all of same to any pledgee entitled thereto or, if none, to Recipient and shall be discharged of all further obligations hereunder.  

6. Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 

  
 1 

 7. You shall be obligated only for the performance of such duties as are specifically set
forth herein and may rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties or their assignees. You shall not be
personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Recipient while acting in good faith and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive
evidence of such good faith.  
 8. You are hereby expressly authorized to disregard any and all warnings given by any of the
parties hereto or by any other person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such
order, judgment or decree of any court, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed,
modified, annulled, set aside, vacated or found to have been entered without jurisdiction.  
 9. You shall not be liable in
any respect on account of the identity, authority or rights of the parties executing or delivering or purporting to execute or deliver the Grant Notice or any documents or papers deposited or called for hereunder.  

10. You shall not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow
Instructions or any documents deposited with you.  
 11. You shall be entitled to employ such legal counsel, including but
not limited to Fenwick & West LLP, and other experts as you may deem necessary properly to advise you in connection with your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation
therefor.  
 12. Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be Secretary of the
Company or if you shall resign by written notice to each party. In the event of any such termination, the Company may appoint any officer or assistant officer of the Company as successor Escrow Agent and Recipient hereby confirms the appointment of
such successor or successors as his attorney-in-fact and agent to the full extent of your appointment.  
 13. If you
reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments.  

14. It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of
the securities, you may (but are not obligated to) retain in your possession without liability to anyone all or any part of said securities until such dispute shall have been settled either by mutual written agreement of the parties concerned or by
a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings.  

15. Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery
or upon deposit in any United States Post Box, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties hereunto entitled at the following addresses, or at such other addresses as a party may designate by
ten (10) days’ written notice to each of the other parties hereto: 

  
 2 

			
	COMPANY:	  	AnaptysBio, Inc.
		  	10421 Pacific Center Court, Suite 200
		  	San Diego, CA 92121
		
		  	Attn: Chief Financial Officer
		
	RECIPIENT:	  	
		
	ESCROW AGENT:	  	AnaptysBio, Inc.
		  	10421 Pacific Center Court, Suite 200
		  	San Diego, CA 92121
		  	Attn: Corporate Secretary

 16. By signing these Joint Escrow Instructions you become a party hereto only for the purpose of said
Joint Escrow Instructions; you do not become a party to the Grant Notice.  
 17. This instrument shall be binding upon and
inure to the benefit of the parties hereto, and their respective successors and permitted assigns. It is understood and agreed that references to “you” or “your” herein refer to the original Escrow Agent and to any and all
successor Escrow Agents. It is understood and agreed that the Company may at any time or from time to time assign its rights under the Grant Notice and these Joint Escrow Instructions in whole or in part.  

18. This Agreement shall be governed by and interpreted and determined in accordance with the laws of the State of Delaware, as such
laws are applied by Delaware courts to contracts made and to be performed entirely in Delaware by residents of that state.  
  

			
	Very truly yours,
	
	ANAPTYSBIO, INC.
		
	By:	 	 
		 	Chief Executive Officer
	
	RECIPIENT
	  

  

	
	ESCROW AGENT
	
	   

	Corporate Secretary

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]